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Dietary bioactive compounds benefit health while some might induce pathological processes.  
Parkinson’s disease (PD) is the second most common neurodegenerative disease.  Braak and Hawkes 
hypothesized that the gastrointestinal tract may be a potential site of neuronal invasion by an “unknown 
pathogen” leading to some Parkinsonism.  Neurotoxin botulinum or ricin can trans-synaptically transport 
in nervous system.  Our hypothesis 1: dietary plant lectins might be responsible for the “unknown 
pathogen” causing PD.  Pomegranate juice (PJ) have antioxidant and anti-obesity effects.  Our hypothesis 
2: PJ increases lifespan in C. elegans and reduces fat storage.  
 Study 1: Post-feeding rhodamine or TRITC tagged dietary lectins was tracked from gut to 
dopaminergic (DAergic) neurons in C. elegans BZ555 (egIs1[Pdat-1::GFP]) that has Green Fluorescent 
Protein (GFP) gene fused to a dopamine transport protein gene labeling DAergic neurons.  Although this 
observation was tested with specific inhibiting sugars (SIS), supplemented with Escherichia coli, the high 
concentrations of monosaccharides necessary may have their own side effects.  Results showed that 
Amaranthus caudatus agglutinin, Euonymus europaeus agglutinin and Arachis hypogaea agglutinin co-
localized with DAergic neurons.  Lectins affected the number, size or intensity of DAergic neurons, 
reduced the mobility and affected the lifespan of C. elegans to different extents, with the SIS either 
augmenting or mitigating the effects.  Our observations are a tantalizing possible explanation for why 
dietary plants have been linked to a risk of developing PD. 
Study 2: Lifespan of C. elegans was increased by PJ treatment in wild type (N2, 56%) and daf-16 
mutant (daf-16(mgDf50)I) (GR1307, 18%), by POMx in N2 (28%) and in GR1307 (10%), or by EA (11%).  
PJ reduced intestinal fat deposition (IFD) in N2 (-68%) or in GR1307 (-33%).  The IFD was increased by 
POMx in N2 (137%) and in GR1307 (26%), by EA in N2 (66%) and in GR1307 (74%), or by UA in N2 
(57%) and in GR1307 (43%).  Both lectins and PJ are bioactive compounds, playing important roles in 
ii 
 
life.  These studies may provide useful information for an alternative etiology of PD and offer solutions 





CHAPTER I.  INTRODUCTION 
1.1 General introduction 
Dietary bioactive compounds such as phytochemicals, vitamins, minerals and fibers contained in 
fruits and vegetables benefit humans and animals [1, 2].  Chemical compounds in fruits and vegetables 
can alter gene expression; have neuroprotective and antiaging effects, and effects in preventing or treating 
chronic diseases including cancer [3, 4].  Plant lectins were discovered over a century ago [5].  
Consumption of lectins contained in seeds or tuber have caused diseases in human beings mainly due to 
damage on intestinal mucosa [6].  Patients suffered vomiting and diarrhea after consuming a diet high in 
red kidney beans containing the lectin phytohemagglutinin in a hospital in 1988 [7].  Lectins are also 
related to disease symptoms in some patients with dysfunction of the immune system [8].  Recent studies 
report that lectins play important roles in plant defense [9] and legume-rhizobial interactions [10].  
Pomegranates (Punica granatum L.) have a high content of polyphenols (1.5%), including ellagic acid 
(EA), gallic acid, anthocynidins, flavan-3-ols, straight chain fatty acids, citric acid, and malic acid.  
Pomegranates consist of about 80% juice and 20% seeds with water (85%), and 10% sugars consisting 
primarily of fructose (2.5 g to 17.6 g/100ml) [11, 12].  Dietary polyphenol antioxidants play important 
roles in health [13-17].  PJ has been shown to extend lifespan in mice [18, 19] and Drosophila 
melanogaster [20].   
The increasing age of people in modernized countries creates a greater burden of chronic diseases 
including cancer, cardiovascular disease, diabetes, and neurodegenerative disorders including PD and 
Alzheimer's disease [21-25], leading to a high cost of health care and a great financial burden to the public 
health system and families [26, 27].  The study of dietary bioactive compounds like lectins and PJ and its 
derivatives in C. elegans organism may provide some useful information for an alternative possible 




1.2 Dietary proteins may be trans-synaptically transported in the nervous system 
Protein toxins are able to survive the harsh environment of cooking process, low pH of stomach, 
and protease digestion of the GI track.  Many of them can penetrate intestine epithelial cells and pass into 
blood or lymphoid circulation [28-30].  Toxins are target specific.  Botulinum neurotoxins (BoNTs) or 
ricin can be trans-synaptically transported in the nervous system causing severe, even lethal damages on 
humans and other mammals [31, 32].  Cholera toxin exerts toxicities only on the epithelial cells of intestine 
and causes symptoms like watery diarrhea [33-35]; tetanus toxin (TeNT) affects neuromuscular junctions 
after being taken up into blood or lymphoid circulation [36]. 
Glycoproteins and glycolipids are major components of eukaryotic cell membranes along with 
phospholipids, and are the main binding receptors for toxins, playing a crucial role in the process of 
binding and internalization [29, 37-39].  Glycoproteins and glycolipids are also essential compounds for 
intercellular communications and reactions to alterations of the cell environment [40].  Both ricin and 
some neurotoxins share similar A-B chain structure; in which chain A is responsible for recognizing 
binding receptors and internalization, and chain B exerts toxicities.  Understanding the underlying 
mechanisms of neurotoxins may help better understand the effects of lectins on neurons. 
1.3 Dietary plant lectins as an “unknown pathogen” in Parkinson’s disease 
Higher prevalence of PD occurs in vegetarians compared to omnivores [41, 42], though 
controversial.  Plant lectins have been used for tracing neurons along nerve fibers in animal studies.  
Dietary toxin proteins can overcome the barriers of digestion systems and cause severe, even lethal 
damage on mammals including humans [31, 32].  We hypothesize that dietary plant proteins traverse the 
GI wall, enter the nerve endings, undergo vesicular transport along nerve fibers, and damage DAergic 
neurons as one etiology of PD.  A recent Danish study showed that patients who had vagal nerves removed 




PD is the second most common degenerative disorder of the central nervous system that impairs 
motor skills and cognitive function, the main symptoms of PD are motion disorders, like muscle rigidity, 
bradykinesia, and tremors [44].  Clinically, PD is characterized by the development of Lewy bodies due 
to aggregation of a-synuclein (α-SYN) in the brain tissue and the partial loss of DAergic neurons in the 
substantia nigra [45].  α-SYN also aggregates in microglia and further leads to PD although the detailed 
mechanism remains unclear [46, 47], while astrocytes convert the PD-causing neurotoxin 1-methyl-4-
phenyl-1,2,3,6-tetrahydropyridine (MPTP) to its active metabolite cation 1-methyl-4-phenylpyridinium 
(MPP+) [48].  However, the mechanism of the formation of Lewy bodies is not clear [49].  The etiology 
of PD is unknown but complex environmental factors play important roles for neurodevelopmental and 
neurodegenerative disorders including PD [50, 51].  Results of large-scale epidemiological studies using 
meta-analysis showed that a statistically positive association exists between PD and pesticide or herbicide 
exposure  [52].  Most of these pesticides share common features, such as the ability to induce oxidative 
stress, mitochondrial dysfunction, α-SYN fibrillization and neuronal cell loss [53].  Insulin dysfunction 
might be associated as a cause of PD though the detailed mechanism is still unclear [54].  Evidence 
indicates that in Caenorhabditis elegans (C. elegans) high glucose concentration (14 mM) increases 
aggregation of α-SYN while restricted glucose concentration reduces it [55].  Exposure to other 
environmental factors such as solvents, metals and other pollutants are also associated with the risk of PD 
in animal models [56, 57].  Despite the long-accepted viewpoint that environment and genetic factors 
might be most related to the etiology of PD, a recent review in 2015 reported that dietary factors like 
vitamins, flavonoids, calorie intake, caffeine, alcohol, and metals may also play a role [53, 58]. 
Plants contain glycoprotein-lectins (“non-immune sugar-binding proteins”) in seeds, fruits, and 
nuts [59], that recognize and reversibly bind specific carbohydrates [60].  They are involved in plant 
defense [9] and legume-rhizobia [10].  They resist gut enzymes maintaining function under adverse 
conditions [61, 62].  They can penetrate the GI tract wall by endocytosis [63], probably by first binding a 
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carbohydrate lectin receptor [64] followed by endocytosis, and, astonishingly, can transfer trans-
synaptically in an antegrade and/or retrograde fashion along nerve fibers [60, 65].  Their medical 
importance is increasingly being recognized by being conjugated with drugs for better drug absorption 
from the GI tract [64, 66-68].  Particularly relevant to the current studies, lectins have been utilized 
extensively for neuronal tracing studies [65, 69].  Ricin (Ricinus communis) as an extremely cytotoxic 
lectin has been studied extensively for its function in retrograde transport.  It is reportedly via a B-chain 
mediated endocytosis, following a translocation of the enzymatically catalyzed A-chain, from the 
endosomes to the Golgi apparatus [70, 71].  This property has been utilized for treatment of malignancies 
at low doses [72, 73].  Lectins have also been conjugated with DNA for enhanced nervous system gene 
delivery [74].  Most dietary plant lectins resist gut enzymes and maintain function under usually adverse 
conditions for proteins [61, 62].   
Most lectins are resistant to mild heat and protease [75], lectin concanavalin A (Con A) from 
Canavalia seeds can survive high cooking temperatures such as 96 °C for up to three hours [76].  These 
characteristics, theoretically, allow lectins to be ‘biologically active’ when reaching their “targets” in vivo.  
Controversial reports suggest that a higher prevalence of PD occurs in vegetarians compared to omnivores 
[41, 77].  The “Vegetarianism in America” study in 2015, published by Vegetarian Times 
(vegetariantimes.com), shows that 3.2 percent of U.S. adults, or 7.3 million people, follow a vegetarian-
based diet and 96.8 percent of U.S. adults or 220.8 million people are omnivores.  A 2195 American 
participants study reported that on average 1/3 of total vegetables people consumed were not cooked, and 
people who consumed more raw vegetables also preferred raw fruits and grains [78].  Taken together, a 
subgroup of dietary plant lectins may act as one of the long-term ‘pathogens’ that slowly cause cellular 
inclusions of α-SYN. 
The Amyotrophic Lateral Sclerosis / Parkinsonism dementia complex (ALS-PDS) in populations from 
Guam, for example, has been linked to a diet rich in cycad seeds (Cycas micronesica) [79, 80].  The cycad 
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seeds contain ß−methylamino-L-alanine (BMAA) which has excitotoxic properties.  Studies on human 
brain tissue of ALS/PDC, ALS, Alzheimer’s disease, PD, Huntington's disease and neurological controls 
indicated that BMAA is present in non-genetic progressive neurodegenerative disease but not in controls 
or genetic-based Huntington's disease [81-84].  Animals fed with purified BMAA, however, do not show 
ALS-PDS traits [85] suggesting that other mechanisms deliver toxin(s) to the target neurons.  A newly 
proposed medical hypothesis suggests that structurally similar glucosides of helicobacter pylori might be 
accountable as neurotoxins [86] though currently unproven.  Several lines of evidence suggest a possible 
role of lectins in neuronal injury.  First, lectins have been detected in Cycas revoluta, which is in the same 
family (Cycadaceae), and genus (Cycas) as Cycas micronesica of Guam [87, 88].  Second, horses 
consuming yellow star thistles (Centaurea solstitialis) show liquid necrosis in the substantia nigra and 
develop nigropallidal encephalomalacia (NPE) symptoms, which are similar to human Parkinsonism.  The 
toxins responsible for NPE have not yet been identified [89].  These studies suggest that lectins might be 
toxic or chaperone carriers of toxins in PD-like diseases.  
1.4 Bioactive compounds of pomegranate juice and extracts improve lifespan in C. elegans 
Dietary polyphenol antioxidants play important roles in health [13-17].  PJ has been shown to extend 
lifespan in mice [18, 19] and Drosophila melanogaster [20].  PJ extract (POMx) potentiates lifespan 
extension with dietary restriction, a finding attributed by polyphenols [18, 19].  POMx and PJ can also act 
as prebiotics, having demonstrated antibacterial properties in vitro, and can block DNA repair and inhibit 
proliferation of breast cancer cells (MCF-7) in vitro, as well as modulate the IGF-IGFBP axis [90-94].  
POMx and PJ also down-regulate androgen-synthesizing genes to induce apoptosis of human prostate 
cells (kappaB-dependent) in vitro and in mice in vivo [95-98].  POMx and PJ decrease prostate specific 
antigen in humans after surgery or radiation [99, 100], inhibit tumor-associated angiogenesis in vitro and 
in vivo [99], suppress inflammatory cell signaling in colon cancer cells [101] (50 mg/L PJ, in vitro), 
improve memory [102] and improve fecundity in humans [20, 103-105].   
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As the main bioactive component, EA is a measure of the quality of PJ extract products [104, 106, 
107].  EA in humans reaches a maximum plasma level in 1 hour (31.9 ng/ml), is eliminated within 4 hours 
[108] and exerts an antioxidant effect [109].   Urolithin acid (UA) is the main active metabolite of EA and 
is formed by colonic microflora.  UA lasts longer in the human body than EA or other EA metabolites [91, 
110], and has better bioavailability [111].  UA also suppresses colorectal, hepatic, and prostate cancers 
synergistically with EA in vitro and in mice in vivo [112-116].  
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CHAPTER II.  DIETARY PLANT LECTINS MAY BE AN ‘UNKNOWN ETIOLOGY’ IN 
PARKINSON’S DISEASE 
PART A.  DIETARY PROTEINS AND TRANS-SYNAPTICAL TRANSPORTATION 
1.1 Introduction 
Study of mechanisms of protein toxins and lectins has been conducted for decades, aimed at 
elucidating the interesting phenomenon that a trace amount of botulinum neurotoxins (BoNTs) or ricin 
could overcome the barriers of digestion systems and cause severe, even lethal damage to mammals 
including humans [1, 2].  The targets of these toxins in humans vary.  For instance, cholera toxin exerts 
toxicities only on epithelial cells of intestine and causes symptoms like watery diarrhea [3-5]; but tetanus 
toxin (TeNT) can cause further damages in neuromuscular junctions after being taken up into blood or 
lymphoid circulation [6].  Several studies have investigated how these protein toxins or ricin survive the 
harsh environment in the stomach and intestine including low pH and protease, and how the toxin 
penetrate intestine epithelial cells into blood or lymphoid circulations [7-9].  Though some mechanisms 
were revealed, the detailed mechanism of this process, especially the process of penetration into the 
neuronal membrane is still under extensive research [10, 11].  Binding strength to neuronal membranes is 
a prerequisite of the following translocations and other toxicities [12, 13]. 
Both ricin and some neurotoxins share similar A-B chain structure; in which chain A is responsible 
for recognizing binding receptors and internalization, and chain B exerts toxicities.  Other lectins can 
recognize special binding sites on neuron membranes and then build communicating connections with 
neurons.  In this chapter, the travel of neurotoxins from intestine to central nervous system was covered 
and the stress was placed on how neurotoxins were retrograde transported from axon to central nerve.  
This part focused on protein toxins because of severe threat to human beings and have been more studied.  
Understanding the underlying mechanisms would help design new drugs and better understand the effects 




1.2 Protein toxins 
1.2.1 Botulinum neurotoxins and tetanus neurotoxin 
1.2.1.1 Structure components 
BoNTs and TeNT have been studied together in most cases because they share similar A-B chain 
structures, employ similar pathways to exert toxicities; and attack neurons only [6, 14, 15].  BoNTs have 
seven serotypes, including type A-G.  The analysis of protein sequences of seven serotypes of BoNTs and 
TeNT indicates sequence homology [16, 17].  In addition, BoNTs and TeNT cause similar symptoms of 
paralyses because they both inhibit the release of neurotransmitter via zinc-dependent cleavage of protein 
components [15].  The main difference between them is that BoNTs target neuromuscular conjunctions 
while TeNT plays roles at neuron-neuron junctions. 
Properties are determined by structures.  In the wild with adequate moisture like in the soil, BoNTs 
exist in the form of binding to a small complex called non-toxic neurotoxin-associated proteins (NAPs, 
Figure 1), which is composed of Hemagglutinin (HA) and non-toxic non-HA (NTNHA) [18, 19]. 
 
Figure 1. Composition of BoNTs complex. 
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The structure of NTNHA protein and BoNTs shows mirror symmetry so that they could bind tightly 
with each other via multivalent bonds.  This strong binding shield BoNTs from harsh environments like 
low pH and proteases [20].  After surviving the harsh environment in GI tract and penetrating the GI wall, 
BoNTs arrive at a moderate environment like blood or lymphoid circulation, where BoNTs are released 
from the complex and at this time they can travel freely in vivo [21]. 
1.2.1.2 Neurotoxins absorbed from GI tract to circulation and up-taken to nerve endings 
After surviving harsh intestinal environments, BoNTs need to overcome the intestinal barrier 
before entering vascular circulation.  Fujinaga et al. in 2013 reported that three steps were involved in 
penetration through the intestinal epithelial barrier, including transcytosis, barrier disruption and 
absorption from damaged barrier (Figure 2) [19].  In detail, two different pathways are involved in the 
first step transcytosis.  The first pathway is associated with the binding domain of the heavy chain, which 
facilitates the binding and transcytosis of the whole toxin.  BoNT/A mainly takes advantage of this 
pathway; however, the detailed mechanisms underlying this pathway are still unknown.  Couesnon et al. 
proposed that Caco-2 and m-ICc 12 cells can absorb the binding domain of the heavy chain by a Cdc-42-
dependent and clathrin-independent pathway.  Recently, Couesnon et al. further proposed that 
neuroendocrine intestinal crypt cells play an important role in transcytosis [22, 23].  The second pathway 
is associated with HA, which could promote the binding of BoNTs with intestinal barrier due to its 
carbohydrate-binding properties and the ability to transit the barrier.  Fujinaga et al. reported that HA 
plays an important role in facilitating the binding of BoNTs complex to the epithelial lining [24].  HA is 
also involved in internalization of BoNT/C and BoNT/D complex into the intestinal epithelial barrier [25].  
The third step is disruption of the epithelial barrier after BoNTs are transferred to the basolateral surface, 
facilitated by HA.  BoNT/A and BoNT/B would not cause some cytotoxic effects in epithelial cells during 
the disruption [26], however, BoNT/C might do so [27].  The last step is release of BoNTs from the 




Figure 2. Three steps involved in the process of penetration into the intestinal epithelial barrier, including 
transcytosis, barrier disruption and absorption from damaged barrier. 
 
1.2.1.3 Internalization into neurons 
After entering the blood or lymphatic stream, neurotoxins are transported to neuromuscular 
junctions.  Four steps are required for BoNTs and TeNT to enter neurons and exert toxicities (Figure 3).  
After entering into neuron terminals, BoNTs’ effects are mainly restricted to the neuromuscular 
conjunction, which prevents release of synaptic vesicles from cell membranes through three different 
pathways as mentioned above; however, TeNT is retrograde transported to neuron soma in the spinal cord 
and trans-synaptically transported to the axon of the next neuron [28]. 
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The first step is membrane binding, early research reported that BoNTs and TeNT bound to 
gangliosides or glycosphingolipids which were found particularly in the outer leaflet of neuronal cell 
membranes [29, 30].  Later studies suggested that BoNTs and TeNT bind to more than a single receptor, 
and a dual-receptor theory was then proposed.  Strong evidence for this dual-receptor theory is that the 
binding of TeNT to rat brain membrane was greatly decreased but not abolished after protease 
pretreatment, implying that other kinds of protein receptors are involved in binding.  In detail, the dual-
receptor theory proposed that BoNTs and TeNT bound to complex polysialogangliosides first, including 
GD1b, GT1b and GQ1b, which are abundantly present on the outer leaflet of neuronal membranes; 
thereafter, they further bind to more sparsely distributed protein receptor(s).  Toxins accumulate first on 
the membrane surfaces, and then further interact with protein receptors to complete the second step of 
binding.  Rummel described the detailed pathway of the first step in 2013 [31].   
The second step is known as internalization, after toxins bind to the surface receptors, acid 
compartments are formed with the endocytic process of toxins, where temperature and available energy 
could affect this process [16].  
The third step is translocation.  After BoNTs and TeNT are transported to acidic compartments, 
the compartments depart the internal cell surface and enter the cytosol.  BoNTs and TeNT utilize different 
pathways for translocation from compartments into cytosol.  Due to the low pH in the compartments, the 
L chain of the BoNTs would be rearranged; leading to higher hydrophobicity, which makes it easier to 
traverse the lipid bilayer [16, 32].  By this step, the light chains of BoNTs are freely available in the cytosol 
of the neuron cells. 
The fourth step is intracellular action, which mainly inhibits the release of neurotransmitters from 
neurons into neuromuscular junction.  As shown in Figure 3, the L chain of the toxin cleaves essential 




Figure 3. Four steps involved in the internalization and toxic effects. 
1.2.2 Shiga toxin 
Shiga toxin inhibits protein synthesis in target cells [33].  Globotriaosylceramide (Gb3), the special 
glycolipid receptor recognized by shiga toxin, was first isolated from both HeLa cells and rabbit jejunal 
mucosa [34].  Shiga toxin has two sub-types; Stx1 and Stx2, both of which feature A-B5 structure, where 
one A-subunit is the active component and five B-subunits are responsible for binding [35].  Stx2 causes 
more severe damage than Stx1 which only causes some infections [36-38].  
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Gb3 was first found in the rat sensory neurons and in rabbit brain capillaries by 
immunohistochemistry [39].  Takahashi, K. first reported that Stx2 might damage neuron cells indirectly 
using a rabbit model [40].  Other studies reported that Stx2 induced a glial lamellipodia-like process 
between presynapse and motoneuronal soma, and proposed that neurons were the primary target of Stx2, 
which could lead to paralysis [35].  Stx2 was further reported to induce expression of Gb3 in neurons and 
cause dendritic abnormalities in rat brains [41], and to exert direct cytotoxic effect in the thalamus in rats 
[42]. 
Shiga toxin employs a clathrin dependent mechanism to enter the cell, binding to glycolipid ligand 
and endocytosed from coated pits [43, 44].  Binding sites are randomly located on cell membranes, but if 
the temperature reaches 37 ℃, the binding site Gb3 will concentrate in coated pits.  Binding of the subunit 
B to Gb3 causes induction of narrow tubular membrane invaginations, which drives formation of inward 
directed membrane tubules for bacterial uptake into the cell.  These tubules are essential for the uptake of 
shiga toxin into host cells [45]. 
To sum up, neurotoxicity of shiga toxin is mainly due to the subtype Stx2.  Gb3 is the primary 
receptor on neuron cell membranes that bound to Stx2, however, the detailed mechanism of binding and 
the following internalization is still not clear. 
1.3 Lectins 
1.3.1 Ricinus communis agglutinin (RCA) 
Ricin, synthesized and stored in the endosperm cells of maturing Ricinus communis seeds (castor 
beans) is a heterodimeric plant protein that has emerged as the first well-known lectin due to its extremely 
high toxicity of trace doses and its special A-B chain structure [46, 47].  Similar to BoNTs and TeNT, 
ricin utilizes the A-B mechanism to penetrate cell membrane.  Chain B of ricin attaches to the cell surface 
first and then the protein undergoes endocytosis into cells.  Ricin inhibits the synthesis of protein 
enzymatically after its chain A enters cytosol and removes a specific adenine residue from the 28S 
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ribosomal RNA (28SrRNA) of the large subunit of eukaryotic ribosomes [48], other toxins share the 
similar mechanisms include diphtheria toxin, Shiga toxin, Pseudomonas exotoxin A, abrin and modeccin 
[49].   
Chain B has special binding sites for galactose [50]; galactose exists in many cell membranes 
because it is widely present in glycoproteins and glycolipids, which are the major components of cell 
membranes [51], thus ricin is bound to the cell surfaces.  Other cell surface receptors include N-
acetylgalactosamine, glycoproteins, glycolipids or mannose receptors [52].  After chain B successfully 
binds to cell surfaces, ricin utilizes both clathrin-dependent and clathrin-independent pathways including 
caveolae and macropinocytosis to enter cells [53-56].  Ricin mainly utilizes clathrin-coated pits to be 
internalized, but if this pathway is blocked, ricin could still be endocytosed by clathrin-independent 
pathways [57].  Catherin-dependent mechanisms are well studied, which is a receptor-mediated uptake of 
proteins.  Special protein motifs like tyrosine residue in the cytosolic tail of the receptors is necessary for 
the uptake in this mechanism [57, 58].  In detail, chain B of ricin is binding to the galactosyl-residues in 
cell surface and then internalized [59].  Clathrin-independent mechanism was proposed based on the 
finding that clathrin-dependent endocytosis was inhibited by transfection of Cos-7 cells with a mutant of 
the 100~kDa GTPase dynamin, whereas fluid-phase uptake still happened [57, 60], this suggests that 
clathrin-dependent pathway is not the only pathway that ricin employed.  The endocytosis of ricin is 
reduced to about 50% when the clathrin-dependent pathway is inhibited [61].   
Ricin’s toxicity largely depends on the exposure route, ingestion mainly caused mass fluid loss by 
producing mucosal injuries, but injection would cause severe damage by inhibiting the synthesis of 
proteins in cells [62].  Ricin is able to be transported from peripheral nerves to neurons retrograde,  called 
‘suicide transport’ [63].  Rat studies showed that 0.2 microgram of ricin caused heavy fiber degeneration 
in the sciatic nerve proximal to the injection site, but not in a nearby tributary nerve [64], which suggested 
that ricin can produce a selective and severe lesion by retrograde "suicide transport".  Injection of ricin 
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bilaterally in the sciatic nerve in rats induces the loss of motor neurons, leading to lower limb paralysis 
and the deficits that occurs in diseases like amyotrophic lateral sclerosis (ALS) and infantile progressive 
spinal muscular atrophy (SMA) [65, 66].  Ricin also affects the glial cells in addition to the degeneration 
of motor neurons in rats.  Injection of ricin into rat facial nerve causes the degeneration of facial motor 
neurons, local microglial cells respond to nerve crush by rapid proliferation and phagocytosis of neuronal 
debris.  After nerve crush, the expression of glial fibrillary acidic protein by fibrous astrocytes is enhanced 
[67].  Intact ricin is resistant to heat, freezing and proteolysis [68].  These findings suggested a possible 
route for lectins to transport from peripheral nerves to the central nervous system, which supports the 
hypothesis that dietary plant lectins might affect DAergic neurons and be one potential cause of PD.  
1.3.2 Wheat germ agglutinin (WGA) 
WGA is a plant lectin that has been employed as an anterograde tracer research tool for years.  WGA 
has a unique binding affinity for N-Acetylneuraminic acid, a key component of neuronal membranes 
found in the brain, such as gangliosides which have diverse roles such as cell-to-cell contact, ion 
conductance, as receptors.  WGA also attaches to the protective coating on the nerves known as the myelin 
sheath [69].  The presence of N-acetylglucosamine inhibits interactions between WGA and cell surface, 
implying that WGA could bind to N-acetylglucosamine on cell surfaces [70].  
WGA is endocytosed by nonfenestrated endothelia throughout the central nervous system, WGA 
passes through the blood brain barrier (BBB) through a process called “adsorptive endocytosis”, this 
adsorptive endocytosis was proposed to associate with inclusion of Golgi complex [71, 72].  WGA is 
uptake via adrenergic nerve terminal and then transported retrograde to the superior cervical ganglion [73], 
however, the detailed mechanism is not clear and it is suggested that WGA has a single population of 
binding sites. 
Most recently, Damak, et al. reported that WGA was transported to the geniculate and petrosal 
ganglia, and proposed this uptake and transportation was via across synapses in vesicles [12].  This 
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suggested that WGA bind to N-acetylglucosamine or N-Acetylneuraminic acid on cell surfaces first to 
build some connections, and then by an unknown pathway, WGA is able to form a small channel on the 
cell membrane, followed by formation of vesicles. 
1.3.3 Phaseolus vulgarwas leucoagglutinin (PHA-L) 
PHA-L has been used as an anterograde tracer of pathways of the central nervous system for a long 
time, even though it also shows some extent of retrograde transport [74-78].  In mammals, PHA-L is 
mainly anterograde transported through the nerve system, but some studies reported that PHA-L 
demonstrated almost the same degree of anterograde and retrograde transport in frogs, which might be 
due to different distribution of binding sites on cell membranes between frog and mammals [79]. 
1.3.4 Concanavalin A (Con A) 
Another interesting lectin is Con A, which can bind to neuronal and synaptic membranes extensively 
[80], but the uptake of this lectin is very limited [73].  Similar to WGA, Con A has also been widely 
employed as a tool to study retrograde transport for its special property [81-83].  Con A is taken up by 
adrenergic nerve terminals and transported retrograde to the superior cervical ganglion [73].  The binding 
pattern of Con A suggests that the ability of binding to the cell membranes cannot guarantee following 
internalization; the effective action is a very complicated process requiring several parts to cooperate.  The 
binding site of Con A was confirmed by pre-incubation of Con A with mannose which could greatly 
decrease Con A activity [84]. 
In addition to these lectins, other lectins also have shown the ability of recognizing or binding to 
neurons and their accessories.  In recent years, the unique properties of binding to carbohydrate receptors 
have made lectins powerful research tools for characterizing the distribution of binding sites on cell 
surfaces. 
In 1985, Fabian, R. H. reported the axonal and transneuronal transport of lectins including WGA, 
Pisum Sativum Agglutinin (PSA), Lens Culinaris Agglutinin (LCA), Soybean Agglutinin (SBA), and Con 
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A, and proposed that axonal and transneuronal transport of the lectins likely depended upon their 
respective carbohydrate affinities [83]. 
Silverman reported utilization of plant lectins to study carbohydrates on sensory ganglion cell 
surfaces [85].  In rats, the alpha-D-galactose-specific Griffonia Simplicifolia I-B4 [86] lectin was used to 
characterize galactose-terminal glyco-conjugates on a large subpopulation of small neurons, peripheral 
autonomic, gustatory and visceral sensory, enteric neurons, and the accessory olfactory bulb.  L-fucose-
binding Ulex europaeus-I (UEA) lectin was used to label the substantia gelatinosa in the human spinal 
cord.  In rabbit, a small sensory ganglion cell subset and the spinal cord substantial gelatinosa was co-
labelled by both the GSA and UEA lectins [85].  Other research reported use of eight lectins including 
Con A, Arachis hypogaea agglutinin (PNA), Soybean Agglutinin (SBA), Dolichos Biflorus Agglutinin 
(DBA), Phytolacca americana (PWA), WGA, UEA and PHA from six groups to study the lectin binding 
sites of olfactory receptor neurons, and all of them demonstrated their special binding properties [84].  The 
reveal of sugar-binding site of Con A has facilitated the mechanism research [87]. 
1.4 Discussion 
The structure of neurotoxins and lectins play a key role in the binding and interactions with neurons.  
Special structural characteristics have determined their inherent properties of recognition, binding and all 
other effects.  A-B structure is the most common structure in neurotoxins, in which subunit B is 
responsible for binding while subunit A for toxic effects.  The receptor on cell membranes is another 
important factor that affects the interactions.  For lectins, special receptors on cell membranes determine 
which lectins they can bind to and the intensity of the interactions, but the detailed mechanism is not all 
known.  Other factors may also affect this binding and internalization, for example, cytofluorometric 
quantification study demonstrated that regenerated nerve greatly increased the uptake of Con A and WGA 
in mice [63].  
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However, due to the potent toxic effects and great value of research, it is of high necessity to 
illuminate the mechanism as well as the pathways of these neurotoxins and lectins.  Many researchers 
have been working on the mechanisms and applications of these neurotoxins and lectins, but more efforts 
will be needed.  For example, the mechanisms of the action of Shiga toxin and some lectins are still very 
vague.  Research on lectins has focused on the characterization or monitoring the sugar receptors on cell 
membranes including cancer cells, some studies have started to investigate physiological effects of lectins 
[88, 89].  In a rat study, after oral administration of ricin, the ricin was absorbed from GI tract into blood 
and lymphatic circulation and detected in the liver and spleen [90].  This finding together with ricin’s 
ability of ‘suicide transport’ might suggest that ricin have the ability of traversing the GI tract to enter the 
central nervous system, which supports our hypothesis that dietary plant lectins may have some effects on 
neurons.  The etiology of PD is still not well defined, but the information presented here provides an 
alternative possibility of inducing PD. 
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PART B. DIETARY PLANT LECTINS APPEAR TO BE TRANSPORTED FROM THE GUT 
TO GAIN ACCESS TO AND ALTER DOPAMINERGIC NEURONS OF C. ELEGANS1 
1.1 Introduction 
Could dietary plant proteins, such as lectins, traverse the gut intact, with vesicular transfer to neurons 
and be transported intact along axons to affect DAergic neurons as one etiology of PD?  A recent Danish 
study showed that patients who had vagal nerves removed 20 years ago had a 40% lower incidence of PD 
[1].  Some reports claim that vegetarians have higher rates of PD [2, 3].  This research uses C. elegans as 
a model to investigate dietary lectins transport to DAergic neurons.  
PD is the second most common degenerative disorder of the central nervous system that impairs 
motor skills and cognitive function, the main symptoms of PD are motion disorders, like muscle rigidity, 
bradykinesia, and tremors [4].  A human study with 490 PD patients and 176 health volunteers showed 
that the age is a key factor to the severity of the disease on a motor scale, but shows no difference in non-
motor symptoms, and in men, the phenotype is characterized by upper-body disease while in women by 
postural dysfunction [5].  A survey of 210 PD subjects reported that in general men suffer more than 
women from PD symptoms according to the index of quality of life [6].  Other survey studies reported 
that men are at higher risk of getting PD than women [7-11].  A study of 1,741 subjects compared motor 
and non-motor symptoms between male and female subjects according to their age of symptom onset and 
diagnose, no difference was found between male and female except that women do better than men in 
non-motor symptoms [12].  The incidence of PD in Italian was estimated at 380/100,100 in year 2011 by 
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analyzing drug prescriptions, tax-exemptions as well as hospital discharge records [13].  Longer lifespan 
has resulted in heavy societal financial burden and emotional burden all over the world [14].   
Clinically, PD is characterized by the development of Lewy bodies due to aggregation of a-
synuclein (α-SYN) in the brain tissue and the partial loss of DAergic neurons in the substantia nigra [15].  
α-SYN also aggregates in microglia and further leads to PD though the detailed mechanism remains 
unclear [16, 17].  Astrocytes convert neurotoxin MPTP to its active metabolite MPP+ [18].  However, the 
mechanism of the formation of Lewy bodies is not clear so far [19].  To date, PD cannot be cured though 
some treatments may alleviate the symptoms.  The etiology of PD is unknown but complex environmental 
factors play important roles for neurodevelopmental and neurodegenerative disorders including PD [20, 
21].  Results of large-scale epidemiological studies using meta-analysis showed that a statistically positive 
association exists between PD and pesticide or herbicide exposure  [22], most of these pesticides share 
common features, such as the ability to induce oxidative stress, mitochondrial dysfunction, α-SYN 
fibrillization and neuronal cell loss [23].  Insulin dysfunction might be associated with the cause of PD 
though the detailed mechanism is still unclear [24].  Evidence indicates that in C. elegans high glucose 
concentration (14 mM) increases the aggregation of α-SYN while restricted glucose concentration reduces 
it [25].  Exposure to other environmental factors such as solvents, metals and other pollutants are also 
associated with the risk of PD in animal models [26, 27].  Despite the long-accepted viewpoint that 
environment and genetic factors might be most related to the etiology of PD, a recent review in 2015 
reported that dietary factors like vitamins, flavonoids, calorie intake, caffeine, alcohol, and metals also 
play an important part in the rise and development of PD [23]. 
Plant lectins were discovered over a century ago (see review [28]).  Toxicity of lectins was first 
recognized, independently, by Bruylants and Vennemann [29], Warden and Waddell [30] (described by 
Carl Oppenheimer [31]), and Dixson [32].  Lectin’s hemagglutination property was found by Stillmark in 




“Nobel Prize in Physiology or Medicine 1908” “in recognition of their work on immunity” 
(http://www.nobelprize.org/nobel_prizes/medicine/laureates/1908/).  Thereafter, lectins’ “immunity” 
(mainly hemagglutination of red cells for antigen typing) was used for immunological research (see 
Textbook of Military Medicine [35]).  In 1919, Sumner crystallized (Canavalia ensiformis, Concanavalin 
A) [36].  A half century later, investigators began to determine ABO-blood subtypes due to their sugar-
binding properties, and the word “lectins” was formally coined [37, 38].  Recent studies report that lectins 
play important roles in plant defense (see review by [39] and legume-rhizobial interactions [40].   
Plants contain glycoprotein-lectins (“non-immune sugar-binding proteins”) in seeds, fruits, and 
nuts [41], and recognize and reversibly bind specific carbohydrates [42].  They are involved in plant 
defense [39] and legume-rhizobia [40].  They resist gut enzymes maintaining function under adverse 
conditions [43, 44].  They can penetrate the GI tract wall by endocytosis [45], probably by first binding a 
carbohydrate lectin receptor [46] followed by endocytosis, and, astonishingly, can transfer trans-
synaptically in an antegrade and/or retrograde fashion along nerve fibers [42, 47].  Their medical 
importance is increasingly being recognized by being conjugated with drugs for better drug absorption 
from the GI tract [46, 48-50].  Particularly relevant to the current studies, lectins have been utilized 
extensively for neuronal tracing studies [47, 51].   
Most dietary plant lectins resist gut enzymes and maintain function under usually adverse 
conditions for proteins [43, 44].  Lectins have effects in both pathological and normal processes in living 
organisms due to their carbohydrate-binding properties [52].  Non-toxic lectins, such as tomato lectin and 
wheat germ agglutinin, are suggested to show growth factor activity in the GI tract [43].  Bacteria or 
parasitic protozoa, through their own lectins, attach to carbohydrate receptors on epithelial cells to 
colonize the GI and urinary tracts.  Some lectins are synergistically toxic both locally and systemically to 
experimental animals [43].  Kidney bean lectin (PHA), for example, damages intestinal epithelial cells, 




inhibiting sugars that have competitive binding capacities to lectins by sharing similar terminal structures 
[43, 53].  Likewise, dietary saccharides or glyco-conjugates, such as probiotic agents and milk 
oligosaccharides, may act as receptor analogs or decoys to selectively and competitively reduce lectin 
binding [43, 54, 55].  Soybean lectin has shown potential anticarcinogenic effects [56]. 
Lectins are widely available in seeds, fruits or nuts of fruits and vegetables.  A 2195 American 
participants study reported that on average 1/3 of total vegetables people consumed were not cooked, and 
people who consumed more raw vegetables preferred raw fruits and grains [57].  People in different 
regions of the world have their own preference in consuming certain raw or cooked vegetables, some 
vegetables like tomatoes, sprout soybeans and carrots are more consumed raw, but other vegetables like 
peas are more consumed cooked [57].  Many studies have investigated anticarcinogenic effects of fruits 
and vegetables.  For example, high consumption of fruits and vegetables is negatively related to the 
incidence of cancer in the GI tract [58, 59].  Leafy vegetables have beneficial effects in preventing the 
development of breast cancer [60].  However, consumption of citrus fruits does not have beneficial effects 
on stomach cancer [61].  Human cell membranes have different glycoproteins and carbohydrates due to 
membrane differentiation [62], which may make some people more vulnerable than others.  Elder people 
cannot tolerate raw vegetables as well as cooked vegetables; main symptoms of intolerance include 
diarrhea and vomiting [63].  Interesting, the prevalence of PD is higher in elder people than in young [64].  
Taken together, all this information suggest that people are exposed to lectins daily as they consume 
varieties of fruits and vegetables, raw or cooked. 
Consumption of fruits or vegetables has been reported to cause diseases in human beings mainly 
due to the damage of lectins on intestinal mucosa [65].  Patients suffered vomiting and diarrhea after 
consuming a diet high in red kidney beans containing lectin PHA in a hospital in 1988 [66].  Lectins are 
related to the disease symptoms in some patients with dysfunction of autoimmune system [67].  Overall 




different plants (Table 1).  The content of lectin Con A is as high as 15 mg/gram of seeds, the content of 
lectin UEA I is 0.045 mg/gram.  The food content of lectin LcH, EEA, CSA and DBA is not available.   
Table 1. Summary of lectins contents from literature search 
Lectins Amount (mg/g) Comments 
UEA I 0.045 [68] seeds 
PSA 0.28 – 0.65 [69] seeds 
PHA 1.07 [70] seeds 
PNA 2 [71] seeds 
GNA 2.5 [72] bulb tissue 
AIA 7.2 [73] seeds 
STA 8 [74] tuber 
ACA 1.7 [75] seeds 
WGA 0.16 [76] wheat germ 
SBA 0.2 [77] seeds 
GSL I 0.4 [78] seeds 
Con A 15 [79] seeds 
CPA 0.5 [80] Seeds 
 
Direct evidence of neuronal damage caused by daily exposure to dietary plant lectins is not 
available so far.  Consumption of vegetable products, however, is a common factor in the epidemiology 
of PD-like diseases.  The Amyotrophic Lateral Sclerosis / Parkinsonism dementia complex (ALS-PDS) 
in populations from Guam, for example, has been linked to a diet rich in cycad seeds (Cycas micronesica) 
[81, 82].  The cycad seeds contain ß−methylamino-L-alanine (BMAA) which has excitotoxic properties.  
Studies on human brain tissue of ALS/PDC, ALS, and Alzheimer’s disease, PD, Huntington's disease and 
neurological controls indicated that BMAA is present in non-genetic progressive neurodegenerative 
disease but not in controls or genetic-based Huntington's disease [83-86].  Animals fed with purified 
BMAA, however, do not show ALS-PDS traits [87] suggesting that other mechanisms deliver the toxin(s) 
to target neurons.   
In equine Parkinsonism, consuming yellow star thistles (Centaurea solstitialis) or Russian 
knapweed (Acroptilon repens) causes liquid necrosis in the substantia nigra pars reticulata and the globus 




resemble human idiopathic PD [88].  These observations suggest transport of toxic substances to neurons.  
To date, however, epidemiology has not proven dietary lectins to have a significant impact on neuronal 
degenerative diseases in humans.   
Signature pathologies of PD, e.g., Lewey bodies and aggregated α-SYN occur in neurons of the 
enteric nervous system of the GI wall, in addition to the neurons of the central nervous system (CNS) [89].  
The findings reported here support Braak and Hawkes’ hypothesis that the GI tract may be a potential site 
of neuronal invasion by an “unknown etiologic agent”, potentially responsible for causing some 
percentage of PD [89-93].  Braak and Hawkes’ hypothesis was based on the finding that α-SYN 
immunoreactive inclusions were found in neurons of the submucosal Meissner plexus, whose axons 
project into the gastric mucosa and terminate in direct proximity to fundic glands.  These elements 
provided the first link in an uninterrupted series of susceptible neurons that extend from the enteric to the 
central nervous system.  The existence of such an unbroken neuronal chain lent support to the hypothesis 
that a putative environmental pathogen capable of passing the gastric epithelial lining might induce α-
SYN misfolding and aggregation in specific cell types of the submucosal plexus and reach the brain via a 
consecutive series of projection neurons.  It is suggested herein that one possible etiologic agent could be 
lectins.  
Several animal models have been developed to investigate the etiology and the underlying 
molecular mechanisms of PD.  Neurotoxic models have been most studied and adopted, which are mainly 
using 6-hydroxydopamine (6-OHDA), MPTP/MPP+ or rotenone to induce PD-like motor symptoms in 
animals.  Neurotoxic models share similar mechanisms of inhibiting the level of complex I of the 
respiratory chain, which further leads to the apoptosis of DAergic neurons [94].  Genetic models 
specifically modify certain genes that are related to the etiology of PD.  The main limitation of genetic 
models is that the detailed mechanisms for the effects of genes are still at large though some models have 




 C. elegans as an animal model to study PD was first reported in 2001 [95], and has been widely 
used [96-101].  C. elegans has a high conservation (>65%) of human disease-associated genes [102, 103].  
A total of eight DAergic neurons in the hermaphrodite C. elegans [104-106], respond to signals from 
environmental mechano-sensory stimuli, e.g. exhausted food supply, which has offered molecular, genetic, 
and behavioral tools to aid human disease studies [107-111].   
C. elegans modulates locomotion behavior by using dopamine and serotonin to mediate motor 
circuits in chemical synapses, gap junctions, and neuromuscular junctions [112-114].  Intestinal muscle 
cells are innervated by pharyngeal motor neurons and DAergic neurons via the preanal ganglia.  Structures, 
sensory-motor synapses, gap junction contacts, and activities all resemble those in the mammalian GI 
tract [115, 116].  A typical phenotype of PD in C. elegans caused by the degeneration of DAergic neurons 
is the slowness of the mobility.  In liquid culture, 0.5 mM of MPP+ induces significant degeneration of 
DAergic neurons and reduces the mobility of C. elegans [97, 99].  Due to the automated devices and 
advanced software, tracking and analyzing the mobility of large number of C. elegans at the same time is 
possible today.  
In this study, features of the GFP-dopamine transporter fusion protein C. elegans (egIs1[Pdat-
1::GFP]) were evaluated by the numbers, fluorescent intensity, and sizes of GFP-DAergic neurons.  
Meanwhile, TRITC/rhodamine labeled lectins were also followed post-feeding, to establish the ability of 
lectins to bind or penetrate the GI wall or nerve cells.  The question was whether dietary plant lectins can 
impair or alter apparently lectin-targeted DAergic neurons.  Differences in inherited sugar structures of 
gut and neuronal cell surface may make some individuals more susceptible in this conceptual disease 
model.  The effects of lectins on the mean lifespan and the movement distance and velocity in liquid 
culture in C. elegans were also evaluated.  Our results support Braak and Hawkes’ hypothesis suggesting 





1.2 Materials and methods 
C. elegans egIs1[Pdat-1::GFP] that express GFP in the 8 DAergic neurons [117, 118] and the 
standard food Escherichia coli (E. coli) were obtained from C. elegans Genetics Center (CGC, MN).  The 
C. elegans model does not require regulation of the Institutional Animal Care and Use Committee 
(IACUC). 
1.2.1 Culture Escherichia coli (E. coli, OP50) 
OP50 were cultured by the standard method described elsewhere [119].  Briefly, approximately 10 
µL of stock E. coli solution was added to media and incubated at 37°C for 24h.  The OP50 were then 
plated in PetrifilmTM (3M Corporate, St. Paul, MN) at 37°C for 24h until densities of 5×108 to 5×1011 
colony forming units (cfu/ml) were reached and then were fed to the C. elegans ad libitum [119, 120].  The 
OP50 stock feeding solution was enriched to 2×109cfu/ml by centrifuging at 2,200 g for 10 minutes and 
washed with S-complete buffer twice. 
1.2.2 C. elegans culture 
Mature gravid transgenic C. elegans egIs1[Pdat-1::GFP] were treated with NaOH (1M) and sodium 
hypochlorite solution (5.25%, 5:2 ratio) to dissolve the body and release viable eggs [119].  The eggs were 
hatched overnight fed ad libitum with LB broth (200 µL/well) containing OP50 5x108 – 5x1011 cfu/ml 
[121], after washing with S-complete solution 3 times.  The age-synchronized C. elegans were diluted to 
100 animals/ml, plated in liquid culture in a 96 well plate (120 μL/well, 10-15 animals) [122].   The plate 
was tape sealed, bagged, and covered with aluminum foil to avoid contamination.  All animals were kept 
in a 20C low temperature incubator (Revco Tech., Nashville, NC, USA) throughout the experiments.  
Thirty microliters of 5-Fluoro-2′-deoxyuridine (FUDR, 0.6 mM) solution was added to each well at larvae 
4 stage.  
All treatments were applied at day 3 after hatching.  Four dose responses of twenty lectins were 




groups were fed rhodamine/TRITC-conjugated lectins.  The lectins were incorporated into feeding 
medium with OP50.  Concentrated OP50 were added to each well every other week throughout the 
experiment.  Each group of nematodes was collected and fixed after the first week for the liquid culture 
as described elsewhere [123].  Briefly, after being collected from wells, animals were washed with S-
Basal twice, fixed with paraformaldehyde (4%) over 2h at 4°C and washed with PBS for 5min x 3.  Ten 
microliters of Fluoromount-G (Southern Biotechnology Associates, Birmingham, AL) was applied to a 
glass slide followed by 10 µL of the medium containing C. elegans.  At last, a cover glass was mounted 
on the glass slide. 
1.2.3 Select lectins 
Commercially available plant lectins conjugated with TRITC or rhodamine were purchased from 
EY labs (San Mateo, USA), Vector Labs (Burlingame, USA), or Sigma-Aldrich (St. Louis, USA).  All 
tested lectins were selected from dietary plants or vegetables.  The doses of lectins were determined based 
on previous studies, literature search or recommendations from product specifications. 
1.2.4 Average probability of survival (APS) assay 
All average probability of survival (APS) assays were conducted in liquid culture (96-well plate). 
The animals were synchronized and seeded into each well of a plate (n=10-15) and OP50 was added to 
each well.  Thirty microliters (0.6mM) fluorodeoxyuridine (FUDR) was added to each well and then the 
plate was shaken evenly to sterilize the animals.  Four different treatments (50 µL/treatment, n=6 row) 
including control or serial of lectins were added.  The plate was then covered with aluminum foil. The 
whole procedure was performed in a dark room to prevent bleaching of fluorophores.  After the plate was 
shaken for 3 minutes, the survival animals were counted every other day until all were dead under an 
inverted microscope (Nikon, Eclipse Ti –S, Japan) at 4x or 10x magnification.  Animals were exposed to 
strong lights to stimulate the movements [124] and the movement of pharynx was checked to confirm 




1.2.5 Mobility analysis 
Mobility analysis was conducted in a 96-well plate.  Animals of larvae 1 stage were seeded into the 
plate with about 20 animals per well.  Each well was treated with MPP+ (0.5 mM) [97] or different lectins.   
All the tested lectins were listed in Table 2.  The plate was kept in a low temperature incubator (20°C) and 
analyzed 48 hours later.  After about 2 minutes of agitation, the plate was placed on the stage of the 
microscope (Nikon, Eclipse Ti –S, Japan).  Using a digital camera, a video of the C. elegans (n=20-25) 
with 20 frames (1 frame/second) was acquired from each well and images stored for offline analysis.  The 
video clips were analyzed by tracking the movement of animals using NIS-Elements Advanced Research 
(version 3.22.11).  The distance and the velocity of the movement were used as a function to characterize 
the effects of lectins on the mobility of C. elegans.  Quantitative indicators were used to compare the 
mobility indicators between treatments and the control. 













ACA 0.032 EEA 0.048 PNA 0.018 PHA-E 0.017 
PSA 0.043 UEA I 0.033 WGA 0.046 LcH 0.05 
S-WGA 0.046 AIA 0.031 CSA 0.065 DBA 0.018 
GNA 0.077 GSL I 0.018 HHA 0.04 PHA-L 0.017 
SBA 0.017 Con A 0.019 CPA 0.047 STA 0.02 
 
1.2.6 Fluorescent microscopy 
The GFP-DAergic neurons were identified by FTIC filter (480Ex/520Em) and the number of GFP-
DAergic neurons counted.  Fluorescent intensity of GFP-DAergic neurons and their average sizes (µm2) 
were determined by NIS-Elements Advanced Research (version 3.22.11) and compared between the 
control and lectins group.  Briefly, a picture was taken for each animal under the FITC filter, in which the 
GFP-DAergic neurons were visible.  A circle was first drawn around each GFP-DAergic neuron and then 




rhodamine-lectins was determined by a TRITC filter (580Ex/620Em) to assess co-localization.  The 
magnitude of the effect(s) of the lectin on the DAergic neurons, the number, fluorescent intensity (arbitrary 
unit), and sizes (µm2) of GFP-DAergic neurons were determined and compared among each group.  Co-
localization was initially identified with an inverted microscopy (Nikon, Eclipse Ti –S, Japan) and then 
confirmed at a Z-axle with laser scanning microscopy (Leica, TCS SP5, Germany). 
1.2.7 Solutions and chemicals 
Standard NGM agar plates (g): NaCl 3.0g, Bacto-agar (Becton, MD) 20g, Bacto-peptone 2.5g 
(Becton, MN), Cholesterol solution 0.1% (0.005/ml 95% ethanol), and dH2O 975ml were mixed.  
Additions to the autoclaved solution (M): CaCl2 1.0 1ml, MgSO4 1.0 1ml, KPO4 pH6 1.0 25ml.  LB Broth: 
25.0g, dH2O 1L (autoclave).  S-basal solution (M): NaCl 0.1, KPO4 pH6 0.05, Cholesterol 0.1%, was 
autoclaved.  PBS (mM): 115 NaCl, 75 Na2HPO4•7H2O, and 7.5 KH2PO4, pH 7.4. 
1.2.8 Statistical analyses 
All results are presented as mean ± S.E.M.  Analyses were carried out using SAS/STAT® software, 
Version 9.4 of the SAS System for Windows (Cary, NC, USA).  Survival curves were displayed by 
binomial probabilities obtained from logistic regression models as surrogates for survival probabilities 
and mean lifespan was estimated via Kaplan-Meier (log-rank).  ANOVA models were used to analyze 
neuron data.  For each group, 10-15 animals were analyzed for liquid culture.  Motion activity analysis 
was performed by Systat software (version 12.5, SigmaPlot for Windows, San Jose, CA, USA).  The 
normality of the data was evaluated before further analysis, nonparametric analysis Kruskal–Wallis with 
Dunn’s method was used to compare between treatments and the control group if the assumption of 
normality was not met.  An alpha level of 0.5 was considered statistically significant. 
1.3 Results 
Diets supplemented with varying concentrations of TRITC-conjugated lectins ACA, EEA and PNA 




associated with GFP-DAergic neurons (Table 3).  The only explanation for this observation is that these 
TRITC-labeled lectins traveled in some manner from the gut to the GFP-DAergic neurons.  We observed 
that some lectins had the following effects:  a) altering the number of DAergic neurons, b) decreasing 
fluorescent intensity of GFP-expressing neurons (less GFP-dopamine transporter), or c) altering neuron 
size.  Other seventeen lectins (Table 4) were not observed to be transported to GFP-DAergic neurons, but 
most of them affected the size, area or intensity of DAergic neurons to different extents, possibly 
indicating that undetectable amounts of these lectins caused the effects, or that some unexplained 
secondary effect of the lectins caused those “pathological effects”.  In addition, the effects of tested lectins 
on the mean lifespan of C. elegans in liquid culture were evaluated.  Lectins affected the mean lifespan of 
C. elegans in different manners.  PHA-E, PSA, UEA I and WGA increased the mean lifespan (P<0.05).  
ACA, EEA, PNA, AIA, CSA, DBA, GNA, GSL I, HHA, PHA-L and SBA reduced the mean lifespan 
(P<0.05).  LcH and S-WGA reduced the mean lifespan at low dose but increased it at high does (P<0.05).  
Con A, CPA and STA did not affect the mean lifespan significantly (P>0.05).  In mobility assay, larvae 1 
stage of C. elegans were fed with different lectins.  The results of mobility assay demonstrated that all 
tested lectins reduced both movement distance and velocity of C. elegans in liquid culture compared with 
the blank control group (OP50 only, P<0.05). 
1.3.1 Lectins co-localized with the GFP-DAergic neurons 
There lectins ACA, EEA and PNA were observed to co-localize with GFP-DAergic neurons in C. 
elegans, affect the size, number or fluorescent intensity of GFP-expressing neurons, and affect the mean 
lifespan (Table 3). 
Amaranthus caudatus agglutinin (ACA)-TRITC co-localized with DAergic neurons at the highest 
dose group (0.32 µM).  As shown in the graph, when the green color from GFP fused DAergic neurons 
(Figure 4a) and the red color from TRITC conjugated ACA (Figure 4b) was overlapped, the co-localized 




from gut to DAergic neurons in C. elegans organism.  ACA did not the affect the number of DAergic 
neurons (Figure 4d).  ACA did not affect the intensity of DAergic neurons (Figure 4e).  Area of DAergic 
neurons was decreased by higher doses of ACA (0.096 µM & 0.32 µM, P<0.05, Figure 4f).  APS was 
decreased dose-dependently (Figure 4g).  The mean lifespan was reduced by all doses (0.032 µM, 0.096 
µM & 0.32 µM) from 18 days to 14, 10 and 7 days dose-dependently (-22%, -44% & -60%, P<0.05, 
Figure 4h). 
Table 3. Lectins detected in the neurons by co-localization 
Lectins Dose (µM) GFP # GFP intensity GFP size Lifespan 
ACA 
0.032     
0.096     
0.32     
PNA 
0.018     
0.054     
0.18     
EEA 
0.048     
0.136     
0.48     
 
 Indicates decreasing trend, P<0.05  
 Indicates increasing trend, P<0.05 
 Indicates no significant alternation, P>0.05  
Arachis hypogaea agglutinin (PNA)-TRITC co-localized with GFP-GAergic neurons after one 
week of treatment (0.018 µM, 0.054 µM & 0.18 µM, Figure 5).  Number of GFP-DAergic neurons was 
increased at the lowest dose (0.018 µM, P<0.05, Figure 5d).  The size and intensity of GFP-GAergic 
neurons was not altered (Figure 5e & Figure 5f).  APS was dose-dependently reduced at all doses (Figure 
5g).  The mean lifespan was reduced by higher doses (0.054 µM and 0.18 µM) from 19 days to 15 days 
and 14 days (-24% and -27%, P<0.05, Figure 5h). 
Euonymus europaeus agglutinin (EEA)-TRITC co-localized with DAergic neurons at the lowest 
dose groups (0.048 µM, Figure 6).  As shown in the graph, when the green color from GFP fused DAergic 




localized area showed bright yellow color (Figure 6c), which demonstrated that EEA was successfully 
transported from gut to DAergic neurons in C. elegans organism.  
 
 
Figure 4. ACA co-localized with GFP-DAergic neurons in C. elegans at the highest dose (0.32 µM).  A) 
GFP-DAergic neurons (green), B) PNA-TRITC in the neuron (red),  C) Co-localization of the GFP-
DAergic neurons in merged A and B (yellow).  D) The number of DAergic neurons was not altered.  E) 
The intensity of DAergic neurons was not altered.  F) The area of DAergic neurons was reduced by two 
higher doses (0.096 µM & 0.32 µM, P<0.05).  G) APS was reduced dose-dependently.   H) The mean 
lifespan was reduced by all doses (0.032 µM, 0.096 µM & 0.32 µM) from 18 days to 14, 10 and 7 days (-






Figure 5. PNA co-localized with GFP-DAergic neurons in C. elegans at all doses (0.018 µM, 0.054 µM 
& 0.18 µM).  A) GFP-DAergic neurons (green), B) PNA-TRITC in the neuron (red),  C) Co-localization 
of the GFP-DAergic neurons in merged A and B (yellow).  D) Number of GFP-DAergic neurons was 
increased at the lowest dose (0.018 µM, P<0.05).  E) The intensity of GFP-DAergic neurons was not 
altered.  F) The size of GFP-DAergic neurons was not altered.  G) APS was dose-dependently reduced at 
all doses.  H) The mean lifespan was reduced by higher doses (0.054 µM and 0.18 µM) from 19 days to 
15 days and 14 days (-24% and -27%, P<0.05).  * indicates statistical significance 
 
The number of DAergic neurons was reduced by the highest dose of EEA (0.48 µM, P<0.05, 
Figure 6d).  The intensity of DAergic neurons was reduced by the highest dose of EEA (0.48 µM, P<0.05, 




6f).  APS was decreased dose-dependently (Figure 6g).  The mean lifespan was reduced dose-dependently 
by all doses (0.048 µM, 0.136 µM & 0.48 µM) from 19 days to 14, 9 and 7 days (-27%, -53% & -62%, 
P<0.05, Figure 6h). 
 
Figure 6. EEA co-localized with GFP-DAergic neurons in C. elegans at the lowest dose (0.048 µM).  A) 
GFP-DAergic neurons (green), B) EEA-TRITC in the neuron (red),  C) Co-localization of the GFP-
DAergic neurons in merged A and B (yellow). D) The number of DAergic neurons was reduced by the 
highest dose (0.48 µM, P<0.05).  E) The intensity of DAergic neurons was reduced by the highest dose of 
EEA (0.48 µM, P<0.05).  F) Area of DAergic neurons was increased by highest dose of EEA (0.48 µM, 
P<0.05).  G) APS was decreased dose-dependently.  H) The mean lifespan was reduced dose-dependently 
by all doses (0.048 µM, 0.136 µM & 0.48 µM) from 19 days to 14, 9 and 7 days (-27%, -53% & -62%, 





1.3.2 Lectins altered the GFP-DAergic neurons without co-localization 
Seventeen lectins PHA-E, PSA, UEA I, WGA, LcH, S-WGA, AIA, CSA, DBA, GNA, GSL I, HHA, 
PHA-L, SBA, Con A or CPA were not observed to co-localize with GFP-DAergic neurons, but most of 
them affected the number, intensity or size of DAergic neurons or the mean lifespan (Table 4). 
Table 4. Lectins which alter number, GFP-intensity, or size of DAergic neurons without observed co-
localization 
 
Lectins Dose (µM) GFP # GFP intensity GFP size Lifespan 
 0.017     
PHA-E 0.054     
 0.17     
 0.043     
PSA 0.129     
 0.43     
 0.033     
UEA I 0.099     
 0.33     
 0.046     
WGA 0.138     
 0.46     
 0.05     
LcH 0.15     
 0.5     
 0.046     
S-WGA 0.138     
 0.46     
 0.031     
AIA 0.093     
 0.31     
 0.065     
CSA 0.195     
 0.65     
 0.018     
DBA 0.054     
 0.18     
 
 Indicates decreasing trend, P<0.05 
 Indicates increasing trend, P<0.05 





Table 4 continued. Lectins which alter number, GFP-intensity, or size of DAergic neurons without 
observed co-localization 
 
Lectins Dose (µM) GFP # GFP intensity GFP size Lifespan 
 0.077     
GNA 0.231     
 0.77     
 0.018     
GSL I 0.054     
 0.18     
 0.04     
HHA 0.12     
 0.4     
 0.017     
PHA-L 0.051     
 0.17     
 0.017     
SBA 0.051     
 0.17     
 0.019     
Con A 0.057     
 0.19     
 0.047     
CPA 0.141     
 0.47     
 0.02     
STA 0.06     
 0.2     
 
 Indicates decreasing trend, P<0.05 
 Indicates increasing trend, P<0.05 
 Indicates no significant alternation, P>0.05 
Phaseolus vulgaris (PHA-E)-rhodamine did not show co-localization with but affected DAergic 
neurons.  The number of GFP-DAergic neurons was not altered (Figure 7a).  The fluorescence intensity 
of GFP-DAergic neurons was increased dose-dependently at all doses (0.017 µM, 0.054 µM & 0.17 µM, 
P<0.05, Figure 7b).  The average size of GFP-DAergic neurons was also reduced at the highest dose (0.17 
µM, P<0.05, Figure 7c).  The APS was increased dose-dependently at lower doses (Figure 7d).  The mean 






Figure 7. PHA-E-rhodamine did not show co-localization with DAergic neurons in liquid culture but 
affected the DAergic neurons.  A) Number of DAergic neurons was not altered.  B) The fluorescence 
intensity of GFP-DAergic neurons was increased dose-dependently at all doses (0.017 µM, 0.054 µM & 
0.17 µM, P<0.05).  C) The average size of GFP-DAergic neurons was also reduced at the highest dose 
(0.17 µM, P<0.05).  D) The APS was increased dose-dependently at lower doses.  E) The mean lifespan 
was increased at a medium dose (0.054 µM) from 17 days to 23 days (39%, P<0.05).  * indicates statistical 
significance. 
 
Pisum Sativum agglutinin (PSA)-rhodamine did not show co-localization with GFP-DAergic 
neurons but affected the DAergic neurons.  The number of DAergic neurons was not altered (Figure 8a).   
The intensity was diminished at the highest dose (0.43 µM, P<0.05, Figure 8b).  The size was reduced at 
the lowest dose (0.043 µM, P<0.05, Figure 8c).  The APS was increased at all doses (Figure 8d).  The 
mean lifespan was increased at doses (0.043 µM & 0.43 µM) from 22 days to 27 days (22% and 23%, 






Figure 8. PSA-rhodamine did not show co-localization with GFP-DAergic neurons but affected the GFP-
DAergic neurons in C. elegans.  A) The number of DAergic neurons was not altered.  B) The intensity 
was diminished at the highest dose (0.43 µM, P<0.05).  C) The size was reduced at the lowest dose (0.043 
µM, P<0.05).  D) The APS was increased at all doses.  E) The mean lifespan was increased at doses (0.043 
µM & 0.43 µM) from 22 days to 27 days (22% & 23%, P<0.05).  * indicates statistical significance. 
 
Ulex Europaeus I (UEA I)-TRITC did not show co-localization with GFP-DAergic neurons in C. 
elegans but affected the DAergic neurons.  The number of DAergic neurons was not altered (Figure 9a).  
The intensity was diminished at all doses (0.033, 0.099 & 0.33 µM, P<0.05, Figure 9b).  The size was 
reduced at all doses (0.033, 0.099 & 0.33 µM, P<0.05, Figure 9c).  The APS was increased at the low dose 
(Figure 9d).  The mean lifespan was increased by low dose (0.033 µM) from 22 days to 25 days (13%, 
P<0.05, Figure 9e). 
Triticum vulgaris agglutinin (WGA)-rhodamine was not detected as transported to but affected 
DAergic neurons.  The number of DAergic neurons was not altered (Figure 10a).  The intensity of the 
GFP-DAergic neurons was increased at the highest dose (0.46 µM, P<0.05, Figure 10b).  The area of the 




(Figure 10d).  The mean lifespan was increased at the highest dose (0.46 µM) from 20 days to 24 days 
(22%, P<0.05, Figure 10e). 
 
 
Figure 9. UEA I-TRITC did not show co-localization with GFP-DAergic neurons but affected the DAergic 
neurons.  A) The number of DAergic neurons was not altered.  B) The intensity was diminished at all 
doses (0.033, 0.099 & 0.33 µM, P<0.05).  C) The size was reduced at all doses (0.033, 0.099 & 0.33 µM, 
P<0.05).  D) The APS was increased at the low dose.  E) The mean lifespan was increased by low dose 
(0.033 µM) from 22 days to 25 days (13%, P<0.05).  * indicates statistical significance. 
 
Lens culinaris (LcH)-TRITC was not detected as transported to but affected DAergic neurons.  
The number of DAergic neurons was increased at low and high doses (0.05 µM & 0.5 µM, P<0.05, Figure 
11a).  The intensity of the GFP-DAergic neurons was increased at the lowest dose (0.05 µM, P<0.05, 
Figure 11b).  The area of the DAergic neurons was not altered (Figure 11c).   The APS was increased at 
the lowest dose and reduced at the highest dose (Figure 10d).  The mean lifespan was increased at the 
lowest dose (0.05 µM) from 18 days to 23 days (27%, P<0.05), and decreased at the highest dose (0.5 µM) 






Figure 10. WGA-rhodamine affected the intensity and area of DAergic neurons.  A) The number of 
DAergic neurons was not altered.  B) The intensity of the GFP-DAergic neurons was increased at the 
highest dose (0.46 µM, P<0.05).  C) The area of the DAergic neurons was reduced at all doses (P<0.05).  
D) The APS was increased at all doses.  E) The mean lifespan was increased at the highest dose (0.46 µM) 
from 20 days to 24 days (22%, P<0.05).  * indicates statistical significance. 
 
Lens culinaris (LcH)-TRITC was not detected as transported to but affected DAergic neurons.  
The number of DAergic neurons was increased at low and high doses (0.05 µM & 0.5 µM, P<0.05, Figure 
11a).  The intensity of the GFP-DAergic neurons was increased at the lowest dose (0.05 µM, P<0.05, 
Figure 11b).  The area of the DAergic neurons was not altered (Figure 11c).   The APS was increased at 
the lowest dose and reduced at the highest dose (Figure 10d).  The mean lifespan was increased at the 
lowest dose (0.05 µM) from 18 days to 23 days (27%, P<0.05), and decreased at the highest dose (0.5 µM) 





Figure 11. LcH-TRITC was not detected as transported to but affected DAergic neurons.  A) The number 
of DAergic neurons was increased at low and high doses (0.05 µM & 0.5 µM, P<0.05).  B) The intensity 
of the GFP-DAergic neurons was increased at the lowest dose (0.05 µM, P<0.05).  C) The area of the 
DAergic neurons was not altered.  D) The APS was increased at the lowest dose and reduced at the highest 
dose.  E) The mean lifespan was increased at the lowest dose (0.05 µM) from 18 days to 23 days (27%, 
P<0.05), and decreased at the highest dose (0.5 µM) to 12 days (37%, P<0.05).  * indicates statistical 
significance. 
 
Triticum vulgaris (Succinylated) S-WGA-rhodamine did not show co-localization but affected 
DAergic neurons in C. elegans.  The number of the GFP-DAergic neurons was decreased at lower doses 
(0.046 µM & 0.138 µM, P<0.05, Figure 12a).  The fluorescent intensity of GFP-DAergic neurons was 
increased at all doses (0.046 µM, 0.138 µM & 0.46 µM, P<0.05, Figure 12b).  The size of GFP-DAergic 
neurons was decreased at all doses (0.046 µM, 0.138 µM & 0.46 µM, P<0.05, Figure 12c).  The APS 
was increased at a lower dose, and decreased at a higher dose (Figure 12d).  The mean lifespan was 
increased at the lowest dose (0.138 µM) from 21 days to 23 days (9%, P<0.05), and decreased at the 






Figure 12. S-WGA-rhodamine affected GFP-DAergic neurons in C. elegans.  A) The number of the GFP-
DAergic neurons was decreased at lower doses (0.046 µM & 0.138 µM, P<0.05).  B) The fluorescent 
intensity of GFP-DAergic neurons was increased at all doses (0.046 µM, 0.138 µM & 0.46 µM, P<0.05).  
C) The size of GFP-DAergic neurons was decreased at all doses (0.046 µM, 0.138 µM & 0.46 µM, P<0.05).  
D) The APS was increased at a low dose, and decreased does-dependently at higher doses.  E) The mean 
lifespan was increased at the lowest dose (0.138 µM) from 21 days to 23 days (9%, P<0.05), and decreased 
at the highest dose (0.46 µM) to 12 days (-43%, P<0.05).  * indicates statistical significance. 
 
Artocarpus integrifolia agglutinin (AIA)-TRITC did not show co-localization and did not affect 
DAergic neurons in C. elegans.  The number of the GFP-DAergic neurons was not altered (Figure 13a).  
The fluorescent intensity of GFP-DAergic neurons was not altered by AIA (Figure 13b).  The size of GFP-
DAergic neurons was not altered by AIA (Figure 13c).  The APS was decreased at all doses (Figure 13d).  
The mean lifespan was decreased at all doses (0.046 µM, 0.138 µM & 0.46 µM) from 24 days to 15 days, 





Figure 13. AIA-TRITC did not show co-localization and did not affect DAergic neurons in C. elegans.  
A) The number of the GFP-DAergic neurons was not altered.  B) The fluorescent intensity of GFP-
DAergic neurons was not altered.  C) The size of GFP-DAergic neurons was not altered.  D) The APS 
was decreased at all doses.  E) The mean lifespan was decreased at all doses (0.046 µM, 0.138 µM & 0.46 
µM) from 24 days to 15 days, 13 days and 11 days (-36%, -47% & -56%, P<0.05).  * indicates statistical 
significance. 
 
Cytisus scoparius agglutinin (CSA)-TRITC did not show co-localization but affected DAergic 
neurons in C. elegans.  The number of the GFP-DAergic neurons was reduced at the highest dose (0.65 
µM, P<0.05, Figure 14a).  The fluorescent intensity of GFP-DAergic neurons was not altered at all doses 
(Figure 14b).  The size of GFP-DAergic neurons was increased at all doses (0.065 µM, 0.195 µM & 0.65 
µM, P<0.05, Figure 14c).  The APS was decreased at the highest dose (Figure 14d).  The mean lifespan 





Figure 14. CSA-TRITC did not show co-localization but affected DAergic neurons in C. elegans.  A) The 
number of the GFP-DAergic neurons was reduced at the highest dose (0.65 µM, P<0.05).  B) The 
fluorescent intensity of GFP-DAergic neurons was not altered at all doses.  C) The size of GFP-DAergic 
neurons was increased at all doses (0.065 µM, 0.195 µM & 0.65 µM, P<0.05).  D) The APS was decreased 
at the highest dose.  E) The mean lifespan was reduced at the highest dose (0.65 µM) from 18 days to 14 
days (-22%, P<0.05).  * indicates statistical significance. 
 
Dolichos biflorus agglutinin (DBA)-rhodamine did not show co-localization with GFP-DAergic 
neurons but affected the size and fluorescent intensity of DAergic neurons in C. elegans.  As shown in the 
graph, the number of DAergic neurons was not altered (Figure 15a).  The fluorescent intensity of GFP-
DAergic neurons was increased at the lowest dose (0.018 µM, P<0.05, Figure 15b).  The size of GFP-
DAergic neurons was increased in a dose-dependent trend at all doses (0.018 µM, 0.054 µM & 0.18 µM, 
P<0.05, Figure 15c).  The APS was increased at a lower dose but decreased at higher doses (Figure 15d).  






Figure 15. DBA-TRITC did show co-localization but affected the DAergic neurons in C. elegans. A) The 
number of DAergic neurons was not altered.  B) The fluorescence intensity of GFP-DAergic neurons was 
increased at the lowest dose (0.018 µM, P<0.05).  C) The size of GFP-DAergic neurons was increased in 
a dose-dependent trend at all doses (0.018 µM, 0.054 µM & 0.18 µM, P<0.05).  D) The APS was increased 
at lower dose, and decreased at higher doses.  E) The mean lifespan was reduced at the highest dose (0.18 
µM) from 19 days to 11 days (-43%, P<0.05).  * indicates statistical significance. 
 
Galanthus nivalis agglutinin (GNA)-rhodamine did not show co-localization with GFP-DAergic 
neurons or affect the DAergic neurons.  The number of DAergic neurons was not altered (Figure 16a).  
The fluorescence intensity of GFP-DAergic neurons was not altered (Figure 16b).  The size of GFP-
DAergic neurons was not altered (Figure 16c).  The APS was reduced at all doses (Figure 16d).  The 
mean lifespan was reduced at higher doses dose-dependently (0.077 µM & 0.231 µM) from 24 days to 






Figure 16. Galanthus nivalis agglutinin (GNA)-rhodamine did not show co-localization with GFP-
DAergic neurons or affect the DAergic neurons.  A) The number of DAergic neurons was not altered.  B) 
The fluorescence intensity of GFP-DAergic neurons was not altered.  C) The size of GFP-DAergic neurons 
was not altered.  D) The APS was reduced at all doses.  E) The mean lifespan was reduced at higher doses 
(0.077 µM & 0.231 µM) from 24 days to 20 days and 19 days (-16% & -23%, P<0.05).  * indicates 
statistical significance. 
 
Griffonia Simplicifolia (GSL I)-TRITC did show co-localization but affected the DAergic neurons 
in C. elegans.  The number of the GFP-DAergic neurons was not altered in any tested doses (Figure 17a).  
The fluorescence intensity of GFP-dopamine transporter protein in DAergic neurons was dose-
dependently increased at all doses (0.018 µM, 0.054 µM & 0.18 µM, P<0.05, Figure 17b).  The size of 
GFP-DAergic neurons was not altered (Figure 17c).  The APS was dose-dependently decreased at all 
doses (Figure 17d).  The mean lifespan was decreased at the highest dose (0.18 µM) from 17 days to 10 






Figure 17. GSL I-TRITC did show co-localization but affected the DAergic neurons in C. elegans. A) The 
number of the GFP-DAergic neurons was not altered.  B) The fluorescence intensity of GFP-dopamine 
transporter protein in DAergic neurons was dose-dependently increased at all doses (0.018 µM, 0.054 µM 
& 0.18 µM, P<0.05).  C) The size of GFP-DAergic neurons was not altered.  D) The APS was dose-
dependently decreased at all doses.  E) The mean lifespan was decreased at the highest dose (0.18 µM) 
from 17 days to 10 days (-37%, P<0.05).  * indicates statistical significance. 
 
Hippeastrum hybrid agglutinin (HHA)-TRITC did show co-localization but affected the DAergic 
neurons in C. elegans.  The number of the GFP-DAergic neurons was not altered (Figure 18a).  The 
fluorescence intensity of GFP-dopamine transporter protein in DAergic neurons was increased at all doses 
(0.04 µM, 0.12 µM & 0.4 µM, P<0.05, Figure 18b).  The size of GFP-DAergic neurons was increased at 
the lowest dose (0.04 µM, P<0.05, Figure 18c).  The APS was dose-dependently decreased at all doses 
(Figure 18d).  The mean lifespan was decreased at higher doses (0.12 µM & 0.4 µM) from 21 days to 15 






Figure 18. HHA-TRITC did show co-localization but affected the DAergic neurons in C. elegans.  A) The 
number of the GFP-DAergic neurons was not altered.  B) The fluorescence intensity of GFP-dopamine 
transporter protein in DAergic neurons was increased at all doses (0.04 µM, 0.12 µM & 0.4 µM, P<0.05).  
C) The size of GFP-DAergic neurons was increased at the lowest dose (0.04 µM, P<0.05).  D) The APS 
was dose-dependently decreased at all doses.  E) The mean lifespan was decreased at higher doses (0.12 
µM& 0.4 µM) from 21 days to 15 days and 11 days (-29% & -47%, P<0.05).  * indicates statistical 
significance. 
 
Phaseolus vulgaris agglutinin-L (PHA-L)-TRITC did show co-localization but affected the 
DAergic neurons in C. elegans.  The number of the GFP-DAergic neurons was not altered (Figure 19a).  
The fluorescence intensity of GFP-dopamine transporter protein in DAergic neurons was reduced at lower 
doses (0.017 µM & 0.051 µM, P<0.05, Figure 19b).  The size of GFP-DAergic neurons was increased at 
all doses (0.017 µM, 0.051 µM & 0.17 µM, P<0.05, Figure 19c).  The APS was increased at a low dose 
and reduced at higher doses (Figure 19d).  The mean lifespan was reduced at the highest dose (0.17 µM) 





Figure 19. PHA-L-TRITC did show co-localization but affected the DAergic neurons in C. elegans.  A) 
The number of the GFP-DAergic neurons was not altered.  B) The fluorescence intensity of GFP-
dopamine transporter protein in DAergic neurons was reduced at lower doses (0.017 µM & 0.051 µM, 
P<0.05).  C) The size of GFP-DAergic neurons was increased at all doses (0.017 µM, 0.051 µM & 0.17 
µM, P<0.05).  D) The APS was increased at a low dose and reduced at higher doses.  E) The mean lifespan 
was reduced at the highest dose (0.17 µM) from 20 days to 13 days (-34%, P<0.05).  * indicates statistical 
significance. 
 
Soybean agglutinin (SBA)-TRITC did show co-localization but affected the DAergic neurons in 
C. elegans.  The number of the GFP-DAergic neurons was decreased at the lowest dose (0.017 µM, P<0.05, 
Figure 20a).  The fluorescence intensity of GFP-dopamine transporter protein in DAergic neurons was not 
altered (Figure 20b).  The size of GFP-DAergic neurons was reduced at the lowest dose (0.017 µM, P<0.05, 
Figure 20c).  The APS was increased at low doses and reduced at a higher dose (Figure 20d).  The mean 





Figure 20. Soybean agglutinin (SBA)-TRITC did show co-localization but affected the DAergic neurons 
in C. elegans.  A) The number of the GFP-DAergic neurons was decreased at the lowest dose (0.017 µM, 
P<0.05).  B) The fluorescence intensity of GFP-dopamine transporter protein in DAergic neurons was not 
altered.  C) The size of GFP-DAergic neurons was reduced at the lowest dose (0.017 µM, P<0.05).  D) 
The APS was slightly increased at low doses and reduced at a higher dose.  E) The mean lifespan was 
reduced at the highest dose (0.17 µM) from 20 days to 14 days (-31%, P<0.05).  * indicates statistical 
significance. 
 
Concanavalin A (Con A)-TRITC did not show co-localization with but affected GFP-DAergic 
neurons in C. elegans.  The number of DAergic neurons was not altered (Figure 21a).  The fluorescence 
intensity of GFP-dopamine transporter protein image in DAergic neurons was increased at the highest 
dose (0.19 µM, P<0.05, Figure 21b).  The size was reduced at medium dose (0.057 µM, P<0.05, Figure 






Figure 21. Con A-rhodamine affected the GFP-DAergic neurons in C. elegans.  A) The number of 
DAergic neurons was not altered.  B) The fluorescence intensity of GFP-dopamine transporter protein 
image in DAergic neurons was increased at the highest dose (0.19 µM, P<0.05).  C) The size was reduced 
at medium dose (0.057 µM, P<0.05).  D) The APS was increased at all doses.  E) The mean lifespan was 
not altered.  * indicates statistical significance. 
 
Cicer arietinum agglutinin (CPA)-TRITC did not show co-localization with but affected GFP-
DAergic neurons in C. elegans.  The number of DAergic neurons was not altered (Figure 21a).  The 
fluorescence intensity of GFP-dopamine transporter protein image in DAergic neurons was reduced at the 
lowest and the highest doses (0.047 µM & 0.47 µM, P<0.05, Figure 22b).  The size of GFP-DAergic 
neurons was reduced at the doses (0.047 µM & 0.47 µM, P<0.05, Figure 22c).  The APS was increased 






Figure 22. CPA-TRITC did not show co-localization with but affected GFP-DAergic neurons in C. 
elegans.  A) The number of DAergic neurons was not altered.  B) The fluorescence intensity of GFP-
dopamine transporter protein image in DAergic neurons was reduced at the doses (0.047 µM & 0.47 µM, 
P<0.05).  C) The size was reduced at the doses (0.047 µM & 0.47 µM, P<0.05).  D) The APS was increased 
at all doses.  E) The mean lifespan was not altered.  * indicates statistical significance. 
 
Solanum tuberosum agglutinin (STA)-TRITC did not show co-localization with but affected GFP-
DAergic neurons in C. elegans.  The number of DAergic neurons was not altered in all tested doses (Figure 
23a).  The fluorescence intensity of GFP-dopamine transporter protein image in DAergic neurons was not 
altered (Figure 23).  The size was reduced at all doses (0.02 µM, 0.06 µM & 0.2 µM, P<0.05, Figure 23c).  
The APS was slightly increased at all doses (Figure 23d).  The mean lifespan was not altered in all tested 






Figure 23. STA-TRITC did not show co-localization with but affected GFP-DAergic neurons in C. elegans.  
A) The number of DAergic neurons was not altered.  B) The fluorescence intensity of GFP-dopamine 
transporter protein image in DAergic neurons was not altered.  C) The size was reduced at all doses (0.02 
µM, 0.06 µM & 0.2 µM, P<0.05).  D) The APS was slightly increased.  E) The mean lifespan was not 
altered.  * indicates statistical significance. 
 
1.3.3 Lectins affect mobility of C. elegans 
Larvae 1 stage of C.elegans were treated with lectins or MPP+ (0.5 mM) as a positive control.  The 
blank control was supplemented with OP50 only.  Travel distance and velocity were evaluated by 
measuring the moving pixels of C. elegans that were displayed in the 20 frames of a video clip.  All 
evaluated twenty lectins significantly reduced the travel distance and velocity of C. elegans showing 
similar effects as the positive control MPP+ compared with the blank control OP50 only (Figure 24, Figure 





Figure 24. Lectins and MPP+ decreased the travel distance of C.elegans compared with the blank control 




Figure 25. Lectins and MPP+ decreased the travel velocity of C.elegans compared with the blank control 





Twenty examined dietary plant lectins conjugated to TRITC or rhodamine were tested in the in 
vivo C. elegans (egIs1[Pdat-1::GFP]) model.  An elevated GFP-dopamine transporter that is expressed 
under control of the dopamine transporter (DAT) gene promoter shows enhanced DAT expression and 
trafficking by the promoter, transcription factor, and nuclear receptor [125].  All three lectins ACA, EEA 
and PNA that co-localized with DAergic neurons decreased the mean lifespan significantly in a dose-
dependent manner. 
Carbohydrate-binding protein toxins are known to survive and traverse the gut intact, as an acutely 
toxic substance and can induce serious life-threatening illness in humans and animals.  Distance 
pathogenicity of botulinum toxin, as well as cholera toxin, impairs the central nervous system [126].  The 
present study was aimed at a new, surprising property of lectins based upon the hypothesis that lectins 
may be transported directly by gut absorption to local neurons and transported axonally to distal neurons 
where they have an anatomical and potentially a physiological pathophysiological effect.  Fluorescent 
intensity and co-localization of lectins was observed to suggest transport to GFP-DAergic neurons.  
Number and area changes of GFP-dopamine receptor fluorescence in DAergic neurons were observed to 
be an effect of the lectins.  Involvement of other pathways like indirect effects by interaction of lectins 
with glial cells that affected DAergic neurons may be possible, as it was reported that in patients with PD 
or Parkinsonism had α-SYN deposited not only in DAergic neurons but also in different kinds of glial 
cells [127-129].  Lectins have been used for histochemistry and neuronal tracing only, but were not 
previously associated with neuronal toxicity [51, 130, 131].  
1.4.1 The occurrence and intensity of individual fluorescently labeled lectins in GFP-DAergic 
neurons detected by co-localization 
Three lectins (ACA, EEA or PNA) appeared to co-localize with a subgroup of GFP-DAergic 




Because some effects were seen in neurons where lectins were not detected, this may be due to 
undetectable amount of transported lectin, or some unexplained indirect effect.  Thus, the number and 
GFP-dopamine transporter image of neurons were also evaluated, even when the fed lectin was not 
detected.  The lack of observation of fluorescence in the neurons using other fed lectins (which, however, 
seemed to affect these neurons) may be due to a variety of characteristics.  For instance, a critical window 
for the lectin to be detectable may have been missed, the lectin may have been partially degraded, losing 
the fluorophore, but still retaining neuron-effective activity, or, more likely, undetectable levels of the 
lectin have activities in the cytoplasm or nucleus.  Future studies with ELISA, other immunocytochemical 
studies or radiolabeling may confirm the transport of small amounts of these specific lectins where an 
effect is observed without fluorescence co-localization being observed.  In addition to the DAergic 
neurons, lectins were found mainly contained in the intestine of C. elegans.  Few amount of lectins were 
also found scattered in the whole body of the animals under the fluorescent microscopy.  Observation of 
lectins in the whole body may suggest that lectins have access to other organs in C. elegans.  ACA was 
first isolated from the seeds of Amaranthus caudatus in 1989 [132], and it has been mainly used to describe 
the recognition and migration of cell surface receptors of cancer cells [133] [134].  EEA was mainly 
known to bind to blood group-related carbohydrates (mainly B and H determinants) and as a new category 
of lectins [135].  Structural analysis of EEA indicated that EEA had a β-trefoil fold similar to ricin B-like 
(R-type) lectins [136], which is known for its neurotoxicity.  PNA was reported to facilitate to isolate 
PNA-binding glycoprotein in central nervous system in humans [137], which implied that further 
interactions between PNA and these proteins was possible.  
1.4.2 Lectin-caused differences in the number of GFP-DAergic neurons 
Four lectins (CSA, EEA, SBA and S-WGA) reduced the number of DAergic neurons, it seemed 
that these effects were related to the dose used.  For CSA and EEA, only the highest dose reduced the 




EEA, low doses of S-WGA reduced the number of DAergic neurons while the highest dose did not.  CSA 
and SBA reduced the number of DAergic neurons.  The reduction of neuron numbers indicated the toxicity 
of these lectins, which was consistent with lifespan results, that both EEA and S-WGA reduced the mean 
lifespan significantly.  The lectin LcH increased the number of DAergic neurons at both the lowest dose 
and the highest dose. 
1.4.3 Lectin feeding effects on the fluorescent intensity of GFP-DAergic neurons 
Four lectins (CPA, EEA, PHA-L, PSA or UEA I) reduced GFP-dopamine transporter fluorescence 
in D-Aergic neurons suggesting damage to DAT, while Con A, CSA, DBA, GSL I, HHA, LcH, PHA-E, 
S-WGA or WGA induced an increase indicating a promotion of DAT in the DAergic neurons.  PSA, in 
some studies, has been shown to be essentially nontoxic in mice both in vivo and in vitro [138].  However, 
toxicity measurements in these studies may not include more subtle long term effects of neuronal damage.  
Although WGA did not affect the number of GFP-DAergic neurons in the present study, and in other 
laboratories, in the in vivo rat gut lumen, reduced expression of heat shock proteins resulting in lowered 
protection and greater permeability of epithelial cells.  WGA also increases thrombin in human platelets, 
and escalates adipogenesis in mesenchymal cells of the mouse limb bud in vitro [50, 139-141], by 
unknown mechanisms.  
1.4.4 Sizes of GFP-DAergic neurons 
ACA, CPA, Con A, PHA-E, PSA, SBA, S-WGA, STA UEA I or WGA significantly reduced the 
size of GFP-DAergic neurons.  Whether these effects are due to damage to the neurons is not known.  
Increased neuron size of a subgroup of GFP-DAergic neurons, however, was also observed with DBA, 
EEA, HHA or PHA-L which may have promoted DAT expression, however, whether decrease or increase 
in the apparent size of neurons has a physiological effect, or indicates lectin-mediated damage is not yet 
known.  Toxicity of some lectins and newly discovered side effects of ingestion of PHA and WGA lectins 




of the GFP-DAergic neurons was significantly reduced suggesting a possible toxic effect of cytoplasmic 
PHA-E.  This observation is in agreement with other studies showing that PHA can damage intestinal 
epithelial cells [53, 142], which was prevented or reversed by a PHA-E SIS sucrose [142].  Interestingly, 
PHA-E did not show significant change in the number and size of GFP-neurons in C. elegans but 
demonstrated enhanced expression of GFP-dopamine transporter fluorescence intensity.  Con A 
strengthens extracellular matrixes by promoting production of proteoglycan in mouse chondrocytes in 
vitro [140].  In our study, Con A altered GFP-DAergic neurons by reducing the area of GFP-dopamine 
transporter fluorescence.   
Some specific beneficial activities of a variety of lectins have been reported [140, 144].  In our 
studies, DBA was observed in the GFP-DAergic neurons which had the effect of increasing the observed 
area of the GFP-labelled DA transporter.  This increase may suggest enhanced DAT expression and 
trafficking, where GFP is expressed under the dopamine transporter (DAT) promoter [125, 145].  A major 
adverse effect of DBA lectin has not been reported elsewhere.  In fact, DBA significantly facilitates 
cartilagenesis and osteogenesis in mouse limb bud mesenchymal cells in vitro [140]. 
1.4.5 Elevated fluorescent intensity and size of DAergic neurons 
These alterations may reflect a relationship with the insulin receptor and DAT. Glucose provides 
a vital energy source for brain and clearly modulates neuronal function [146, 147].  In C. elegans, 
hyperglycemia reduces APS, related to human diabetes.  These relationships in our study, however, may 
represent some signaling interaction of glycemia/insulinemia and DAT.  As with other catecholamine 
neurotransmitters, inhibitory neurotransmitters are inversely proportional to glycemia, and DA kinetics is 
sensitive to hypoglycemia in a complex manner [148].  In rodents, insulin receptors and DAT are densely 
present in substantia nigra, insulin may increase DAT mRNA expression, and glycemic index is inversely 




1.4.6 Lectins affect the lifespan of C. elegans 
 Lectins can be categorized into four groups based on their effects on the mean lifespan of C. 
elegans.  1) Lectins PHA-E, PSA, UEA I or WGA increased the mean lifespan.  2) Lectins ACA, AIA, 
CSA, DBA, EEA, GNA, GSL I, HHA, PHA-L, PNA or SBA reduced the mean lifespan.  3) Lectins LcH 
or S-WGA showed dual effects in affecting the mean lifespan, with low dose increasing and high dose 
decreasing it.  4) Lectins Con A, CPA or STA did not alter the mean lifespan significantly. 
1.4.7 Lectins affect the mobility of C. elegans 
PD includes four cardinal features, tremor, rigidity, bradykinesia (slowness of movement) and 
postural instability, with bradykinesia as the most characteristic and easily recognizable symptom [151]. 
In addition, among the four symptoms, bradykinesia correlates best with the degree of dopamine 
deficiency, rigidity and postural instability correlates less and tremor does not show any correlation [152].  
In this study, two important surrogate markers of movement, distance and velocity were evaluated in C. 
elegans.  C. elegans is a practical and affordable animal model to study symptoms of neurodegenerative 
diseases, as they respond to a wide range of stimuli and exhibit characteristic movement patterns [153].   
MPP+ has been widely used in various animal models to induce symptom of PD, which can be 
selectively taken up by DAergic neurons via DAT[99].  MPP+ (0.5 mM) has been used to induce motor 
symptoms that mimic PD’s in C. elegans, which cause apparent mobility reduction after 48 hours of 
treatment [96, 97, 154].  Present study showed that all twenty lectins evaluated reduced travel distance 
and velocity (P<0.05), mimicking bradykinesia in humans, as the positive control MPP+ (0.5 mM) in C. 
elegans organism.  The decrease of the distance and velocity of animals implies that motor neurons were 
affected, which might be due to neurodegeneration caused by lectins.  This observed reduction in the travel 
distance and velocity was consistent with the reduction of the number, area or intensity of DAergic 
neurons for most tested lectins.  Some lectins like PNA, LcH, AIA, DBA, GNA, GSL I or HAA, were not 




PD like symptoms of slow movement in C. elegans.  This phenomenon might indicate that lectins might 
have other mechanisms in inducing the PD besides affecting DAergic neurons.  α-SYN deposit in both 
DAergic neurons and glial cells, lectins might also affect the glial cells in addition to directly or indirectly 
participate in the development of the PD [128].  The detailed mechanism of bradykinesia remains 
unknown, but a disruption in normal motor cortex activity caused by reduced DAergic function might be 
the main cause of bradykinesia [151].  Functional imaging studies suggest that bradykinesia correlates 
with impairment in the recruitment of cortical and subcortical systems that regulate kinematic parameters 
of movement like velocity [155].  Anatomically, bradykinesia and tremor scores significantly correlate 
with cerebral metabolic rate of glucose inversely in bilateral putamen, the metabolic rate of glucose is 
higher when the bradykinesia is worse [156], which leads to reduction in the muscle force produced at the 
initiation of movement [151].  In a human study, patients with PD were asked to make ballistic elbow 
flexion movements, electromyographic signals were recorded and showed that patients with bradykinesia 
are unable to energize the appropriate muscles to perform long time movements compared with the control 
[157].  Taken together, the results of current study might lend some support to the hypothesis of reduced 
DAergic function caused bradykinesia, and the reduced DAergic neuron number, area or intensity caused 
by lectins correlate with the reduced mobility in C. elegans to some extent. 
Neurotoxins like botulinum toxin or ricin bind to specific receptors on cell membrane, to be 
internalized, and exert toxic effects [158, 159].  Similarly, lectins bind to carbohydrate ligands of targeted 
cells to be functional, producing effects.  Specific sugars may competitively bind and inhibit lectins uptake 
[160].  Structurally similar lectins might share similar binding receptors and compete for each other’s 
binding sites.  The complex GI environment including nutrients and cellular environment might alter the 
absorption of certain lectins and their potential biological consequences [161].  
In a recent Danish report, patients who had vagal nerves removed 20 years earlier had 40% lower 




transport to neurons from the gut, as hypothesized here, removal of the vagal nerve would have prevented 
or reduced this etiology pathway.  Symptoms of motor impairment are typical in PD patients, and 
dysfunction of aspects of the autonomic nervous system are often underrated, such as GI motility [162], 
rapid eye movement [163], etc.  The current study indicates potential transport of some dietary plant 
lectins from the GI tract to the DAergic neurons in C. elegans, with direct or indirect effects on these 
neurons and diverse effects on APS.  This observation may be related to the Braak and Hawkes’ 
hypothesized unknown etiologic agent for PD or related, for example, to damaged DAergic neurons those 
have been found in PD [89, 93].  If related, the process may be gradual, may be additive, related to the 
frequency of consumption of certain lectins, and may be determined by the association of lectins with 
other factors.  Certainly, there is potential for inputs from individual genetic susceptibility, varying sugar 
structures profiles in different cell membranes, the receptivity to endocytosis, a disorder or leakage of the 
GI lining, and dietary content.  Our observations are a tantalizing possible explanation for why dietary 
plants have been linked to a risk of developing PD. 
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CHAPTER III. SPECIFIC INHIBITING SUGARS AFFECT THE EFFECTS OF LECTINS ON 
LIFESPAN AND DOPAMINERGIC NEURONS IN C. ELEGANS 
 
1.1 Disclaimer 
There were anticipated problems with feeding high amounts of sugars to C. elegans as inhibitors of 
lectin binding.  For example, D-galactosamine perfusion in the liver of rats led to D-galactosamine 
accumulate as sugar nucleotides, and reduced the level of uridine diphosphate (UDP), which was needed 
for RNA synthesis [1].  Other problems can arise, for example, feeding xylose to rats and mice cause 
cataracts due to protein cross linking by "non enzymatic glycosylation" [2, 3].  Sucrose has effects on the 
levels of dopamine and opioid mRNA in rat brain similar to the effects of opiate [4].  Other sugars may 
cause similar side effects because they spend considerably more time in the open chain aldehyde or ketone 
form than glucose, which is the evolutionarily chosen circulating sugar in animals for that reason.  
However, we conducted some experiments with simple sugars as inhibitors, which experiments and results 
are described here. 
1.2 Materials and methods 
C. elegans egIs1[Pdat-1::GFP] that express GFP in the 8 DAergic neurons [5, 6] and the standard 
food Escherichia coli (E. coli) were obtained from C. elegans Genetics Center (CGC, MN).  The C. 
elegans model does not require regulation of the Institutional Animal Care and Use Committee. 
1.2.1 Culture Escherichia coli (E. coli, OP50) 
OP50 were cultured by the standard method described elsewhere [7].  Briefly, approximately 10 µL 
of stock E. coli solution was added to media and incubated at 37°C for 24h.  The OP50 were then plated 
in PetrifilmTM (3M Corporate, St. Paul, MN) at 37°C for 24h until densities of 5×108 to 5×1011 colony 
forming units (cfu/ml) were reached and then were fed to the C. elegans ad libitum [7, 8].  The OP50 stock 
feeding solution was enriched to 2×109cfu/ml by centrifuging at 2,200 g for 10 minutes and washed with 




1.2.2 C. elegans culture 
Mature gravid transgenic C. elegans egIs1[Pdat-1::GFP] were treated with NaOH (1M) and sodium 
hypochlorite solution (5.25%, 5:2 ratio) to dissolve the body and release viable eggs [7].  The eggs were 
hatched overnight fed ad libitum with LB broth (200 µL/well) containing OP50 5x108 – 5x1011 cfu/ml [9], 
after washing with S-complete solution 3 times.  The age-synchronized C. elegans were diluted to 100 
animals/ml, plated in liquid culture in a 96 well plate (120μl/well, 10-15 animals) [10].   The plate was 
tape sealed, bagged, and covered with aluminum foil.  All animals were kept in a 20C low temperature 
incubator (Revco Tech., Nashville, NC, USA) throughout the experiments.  Thirty microliters of 5-Fluoro-
2′-deoxyuridine (FUDR, 0.6 mM) stock solution was added to each well at larvae 4 stage.   
All treatments were applied at day 3 after hatching.  Four dose responses of twenty lectins were 
obtained for each culture condition in a dark room.  Control animals were fed with OP50.  Experimental 
groups were fed rhodamine/TRITC-conjugated lectins with or without additional SIS(s).  The SIS, or 
lectin plus SIS were incorporated into feeding medium with OP50.  Each group of nematodes were 
collected and fixed after the first week for the liquid culture as described elsewhere [11].  Briefly, after 
being collected from wells, animals were washed with S-Basal twice, fixed with paraformaldehyde (4%) 
over 2h at 4°C and washed with PBS for 5min x 3.  Ten microliters of Fluoromount-G (Southern 
Biotechnology Associates, Birmingham, AL) was applied to a glass slide followed by 10 µL of the 
medium containing C. elegans.  At last, a cover glass was mounted on the glass slide. 
1.2.3 Select lectins and specific inhibiting sugars (SIS) 
Commercially available plant lectins conjugated with TRITC or rhodamine were purchased from 
EY labs (San Mateo, USA), Vector Labs (Burlingame, USA), or Sigma-Aldrich (St. Louis, USA).  Each 
lectin-SIS-inhibition experiment had a SIS-only control group.  The dose of SIS for each fluorescence-
conjugated lectin was determined by searching histology literature or product manuals.  Doses of lectins 




1.2.4 Average probability of survival (APS) assay 
All average probability of survival (APS) assays were conducted in liquid culture (96-well plate). 
The animals were synchronized and seeded into each well of a plate (n=10-15) and OP50 was added to 
each well.  Thirty microliters (0.6mM) of fluorodeoxyuridine (FUDR) was added to each well to sterilize 
the animals.  Four different treatments (50 µL/treatment, n=6 row) including control, SIS only, or lectin 
plus SIS were added.  The plate was then covered with aluminum foil. The whole procedure was 
performed in a dark room to prevent bleaching of fluorophores.  After the plate was shaken for 3 minutes, 
the survival animals were counted every other day until all were dead under an inverted microscope (Nikon, 
Eclipse Ti –S, Japan) at 4x or 10x magnification.  Animals were exposed to strong lights to stimulate the 
movements [15] and the movement of pharynx was checked to confirm whether the animals were dead 
when they were not moving. 
1.2.5 Fluorescent microscopy 
The GFP-DAergic neurons were identified by FTIC filter (480Ex/520Em) and the number of GFP-
DAergic neurons counted.  Fluorescent intensity of GFP-DAergic neurons and their average sizes (µm2) 
were determined by NIS-Elements Advanced Research (version 3.22.11) and compared among the 
following groups: control, SISs, and lectins plus SIS.  Fluorescent intensity of rhodamine-lectins was 
determined by a TRITC filter (580Ex/620Em) to assess co-localization.  The magnitude of the effect(s) of 
the lectin on the DAergic neurons, the number, fluorescent intensity (arbitrary unit), and sizes (µm2) of 
GFP-DAergic neurons were determined and compared among each group.  Co-localization was initially 
identified with an inverted microscopy (Nikon, Eclipse Ti –S, Japan) and then confirmed at a Z-axle with 
laser scanning microscopy (Leica, TCS SP5, Germany). 
1.2.6 Solutions and chemicals 
Standard NGM agar plates (g): NaCl 3.0g, Bacto-agar (Becton, MD) 20g, Bacto-peptone 2.5g 




Additions to the autoclaved solution (M): CaCl2 1.0 1ml, MgSO4 1.0 1ml, KPO4 pH6 1.0 25ml.  LB Broth: 
25.0g, dH2O 1L (autoclave).  S-basal solution (M): NaCl 0.1, KPO4 pH6 0.05, Cholesterol 0.1%, was 
autoclaved.  PBS (mM): 115 NaCl, 75 Na2HPO4•7H2O, and 7.5 KH2PO4, pH 7.4. 
1.2.7 Statistical analyses 
All results are presented as mean ± S.E.M.  Analyses were carried out using SAS/STAT® software, 
Version 9.4 of the SAS System for Windows (Cary, NC, USA).  Survival curves were displayed by 
binomial probabilities obtained from logistic regression models as surrogates for survival probabilities 
and mean lifespan was estimated via Kaplan-Meier (log-rank).  ANOVA models were used to analyze 
neuron data.  For each group, 10-15 animals were analyzed for liquid culture.  An alpha level of 0.5 was 
considered statistically significant. 
1.3 Results 
Diets supplemented with varying concentrations of TRITC-conjugated lectins and their SIS in liquid 
culture were fed to C. elegans (Error! Reference source not found.).  We observed that some SIS had 
the following effects:  a) enhancing the effects of lectins on the DAergic neurons or mean lifespan, b) 
mitigating the effects of lectins on the DAergic neurons or mean lifespan, or c) reversing the effects of 
lectins on the DAergic neurons or mean lifespan. 
Amaranthus caudatus agglutinin (ACA)-TRITC co-localized with DAergic neurons at the highest 
dose (0.32 µM), with or without the SIS GalNAc.  As shown in the graph, when the green color from GFP 
fused DAergic neurons (Figure 26a) and the red color from TRITC conjugated ACA (Figure 26b) was 
overlapped, the co-localized area showed bright yellow color (Figure 26c), which demonstrated that ACA 
was successfully transported from gut to DAergic neurons in C. elegans organism.  ACA did not the affect 
the number of DAergic neurons (Figure 26d), the intensity of DAergic neurons was reduced by the highest 





Table 5. Effects of lectins combined with specific inhibiting sugars on lifespan and DAergic neurons in 
C. elegans 
 
Lectins Dose (µM) GFP # GFP intensity GFP size Lifespan 
ACA 
0.032     
0.096     
0.32     
EEA 
0.048     
0.136     
0.48     
PNA 
0.018     
0.054     
0.18     
 0.017     
PHA-E 0.054     
 0.17     
 0.043     
PSA 0.129     
 0.43     
 0.033     
UEA I 0.099     
 0.33     
 0.046     
WGA 0.138     
 0.46     
 0.05     
LcH 0.15     
 0.5     
 0.046     
S-WGA 0.138     
 0.46     
 0.031     
AIA 0.093     
 0.31     
 0.065     
CSA 0.195     
 0.65     
 
 Indicates decreasing trend, P<0.05  
 Indicates increasing trend, P<0.05  






Table 5 continued. Effects of lectins combined with specific inhibiting sugars on lifespan and DAergic 
neurons in C. elegans 
 
Lectins Dose (µM) GFP # GFP intensity GFP size Lifespan 
 0.018     
DBA 0.054     
 0.18     
 0.077     
GNA 0.231     
 0.77     
 0.018     
GSL I 0.054     
 0.18     
 0.04     
HHA 0.12     
 0.4     
 0.017     
PHA-L 0.051     
 0.17     
 0.017     
SBA 0.051     
 0.17     
 0.019     
Con A 0.057     
 0.19     
 0.047     
CPA 0.141     
 0.47     
 0.02     
STA 0.06     
 0.2     
 
 Indicates decreasing trend, P<0.05  
 Indicates increasing trend, P<0.05 







Figure 26. ACA co-localized with GFP-DAergic neurons in C. elegans at the highest dose (0.32 µM).  A) 
GFP-DAergic neurons (green), B) PNA-TRITC in the neuron (red),  C) Co-localization of the GFP-
DAergic neurons in merged A and B (yellow).  D) The number of DAergic neurons was not altered. E) 
The intensity of DAergic neurons was decreased by the highest dose (0.32 µM) plus the presence of the 
SIS (GalNAc 1.58 mM). F) The area of DAergic neurons was reduced by two higher doses (0.096 µM & 
0.32 µM, P<0.05) and the highest dose (0.32 µM, P<0.05) when the SIS was present. G) The APS was 
reduced with or without the SIS.  H) The mean lifespan was reduced by all doses (0.032 µM, 0.096 µM 
& 0.32 µM) from 18 days to 14, 10 and 7 days (-22%, -44% & -60%, P<0.05), or by the SIS only from 
18 days to 12 days (-30%, P<0.05).  With the presence of the SIS, the mean lifespan was reduced by higher 
doses (0.096 µM & 0.32 µM) from 12 days to 8 days and 7 days (-32% & -43%, P<0.05).  * indicates 




Area of DAergic neurons was decreased by higher doses of ACA (0.096 µM & 0.32 µM, P<0.05), 
and decreased by the highest dose of ACA plus GalNAc (0.32 µM, P<0.05, Figure 26f).  APS was 
decreased dose-dependently with or without the presence of the SIS (Figure 26g).  The mean lifespan was 
reduced by all doses (0.032 µM, 0.096 µM & 0.32 µM) from 18 days to 14, 10 and 7 days (-22%, -44% 
& -60%, P<0.05), or by the SIS only from 18 days to 12 days (-30%, P<0.05).  With the presence of the 
SIS, the mean lifespan was reduced by higher doses (0.096 µM & 0.32 µM) from 12 days to 8 days and 7 
days (-32% & -43%, P<0.05, Figure 26h). 
Euonymus europaeus agglutinin (EEA)-TRITC co-localized with DAergic neurons at the lowest 
dose (0.048 µM), with or without the SIS lactose.  As shown in the graph, when the green color from GFP 
fused DAergic neurons (Figure 27a) and the red color from TRITC conjugated EEA (Figure 27b) was 
overlapped, the co-localized area showed bright yellow color (Figure 27c), which demonstrated that EEA 
was successfully transported from gut to DAergic neurons in C. elegans organism.  The number of 
DAergic neurons was reduced by the highest dose (0.48 µM, P<0.05), which was blocked by the SIS 
lactose (10 mM, Figure 27d).  The intensity of DAergic neurons was reduced by the highest dose of EEA 
(0.48 µM, P<0.05) which was reversed by the SIS at the lowest dose (0.048 µM, P<0.05).  The SIS did 
not block the effect of the highest dose of EEA in reducing the intensity of DAergic neurons (Figure 27e).  
Area of DAergic neurons was increased by highest dose (0.48 µM, P<0.05), the presence of the SIS 
reduced the magnitude of this effect. Medium dose of EEA plus the SIS reduced the size of DAergic 
neurons (0.136 µM, P<0.05, Figure 27f).  APS was decreased dose-dependently with or without the SIS 
(Figure 27g).  The mean lifespan was reduced dose-dependently by all doses (0.048 µM, 0.136 µM & 
0.48 µM) from 19 days to 14, 9 and 7 days (-27%, -53% & -62%, P<0.05), or by the SIS only from 19 
days to 11 days (-43%, P<0.05).  With the presence of the SIS, the mean lifespan was reduced by higher 






Figure 27. EEA co-localized with GFP-DAergic neurons in C. elegans at the lowest dose (0.048 µM).  A) 
GFP-DAergic neurons (green), B) PNA-TRITC in the neuron (red), C) Co-localization of the GFP-
DAergic neurons in merged A and B (yellow). D) The number of DAergic neurons was reduced by the 
highest dose (0.48 µM, P<0.05), which was blocked by the SIS lactose 10 mM. E) The intensity of 
DAergic neurons was reduced by the highest dose of EEA (0.48 µM, P<0.05) which was reversed by the 
SIS at the lowest dose (0.048 µM, P<0.05).  F) Area of DAergic neurons was increased by highest dose 
of EEA (0.48 µM, P<0.05), the presence of the SIS reduced the magnitude of this effect. Middle dose of 
EEA plus the SIS reduced the size of DAergic neurons (0.136 µM, P<0.05).  G) APS was decreased dose-
dependently with or without the presence of the SIS. H) The mean lifespan was reduced dose-dependently 
by all doses (0.048 µM, 0.136 µM & 0.48 µM) from 19 days to 14, 9 and 7 days (-27%, -53% & -62%, 
P<0.05), or by the SIS only from 19 days to 11 days (-43%, P<0.05).  With the presence of the SIS, the 
mean lifespan was reduced by higher doses (0.136 µM & 0.48 µM) from 11 days to 7 days and 7 days (-




Arachis hypogaea agglutinin (PNA)-TRITC co-localized with GFP-GAergic neurons after one 
week of treatment (0.018 µM, 0.054 µM & 0.18 µM).  As shown in the graph, when the green color from 
GFP fused DAergic neurons (Figure 28a) and the red color from TRITC conjugated EEA (Figure 28b) 
was overlapped, the co-localized area showed bright yellow color (Figure 28c), which demonstrated that 
PNA was successfully transported from gut to DAergic neurons in C. elegans organism.  Number of GFP-
DAergic neurons was increased at the lowest dose (0.018 µM, P<0.05), which was blocked by the SIS 
galactose 200 mM (Figure 28d).  The size and intensity of GFP-GAergic neurons was not altered (Figure 
28e & Figure 28f).  SIS galactose (200 mM) treatment decreased the size of GFP-DAergic neurons (0.054 
µM & 0.18 µM, P<0.05) without altering the number and intensity.  APS was dose-dependently reduced 
at all doses, reversed by SIS, and was reduced by SIS galactose (200 mM) only (Figure 28g).  The mean 
lifespan was reduced by higher doses (0.054 µM and 0.18 µM) from 19 days to 15 days and 14 days (-
24% and -27%, P<0.05), which was reversed in presence of SIS galactose with an increase at the highest 
dose (0.18 µM) from 12 days to 16 days (33%, P<0.05).  The mean lifespan was reduced by SIS only from 
19 days to 12 days (-36%, P<0.05, Figure 28h). 
Phaseolus vulgaris (PHA-E)-rhodamine did not show co-localization with DAergic neurons in 
liquid culture but affected the DAergic neurons.  The number of GFP-DAergic neurons was not altered, 
but reduced at the highest dose with the SIS present (0.17 µM, P<0.05, Figure 29a).  The fluorescence 
intensity of GFP-DAergic neurons was increased dose-dependently at all doses (0.017 µM, 0.054 µM & 
0.17 µM, P<0.05), which was blocked by the SIS at the highest dose (0.17 µM, Figure 29b).  The average 
size of GFP-DAergic neurons was also reduced at the highest dose (0.17 µM, P<0.05), which was 
augmented by the presence of the SIS (Figure 29c).  The APS was increased dose-dependently at lower 
doses, which was blocked by SIS GalNAc (1.58 mM), and was reduced by GalNAc only (Figure 29d), 






Figure 28. PNA co-localized with GFP-DAergic neurons in C. elegans at all doses (0.018 µM, 0.054 µM 
& 0.18 µM).  A) GFP-DAergic neurons (green), B) PNA-TRITC in the neuron (red),  C) Co-localization 
of the GFP-DAergic neurons in merged A and B (yellow).  D) Number of GFP-DAergic neurons was 
increased at the lowest dose (0.018 µM, P<0.05), which was blocked by the SIS galactose 200 mM.  E) 
The intensity of GFP-DAergic neurons was not altered.  F) The size of GFP-DAergic neurons was not 
altered, but was reduced with the presence of the SIS at higher doses (0.054 µM & 0.18 µM, P<0.05).  G) 
APS was dose-dependently reduced at all doses, reversed by SIS, and was reduced by SIS galactose (200 
mM) only.  H) The mean lifespan was reduced by higher doses (0.054 µM and 0.18 µM) from 19 days to 
15 days and 14 days (-24% and -27%, P<0.05), which was reversed in presence of SIS galactose with an 
increase at the highest dose (0.18 µM) from 12 days to 16 days (33%, P<0.05).  The mean lifespan was 
reduced by SIS galactose (200 mM) only from 19 days to 12 days (-36%, P<0.05).  * indicates statistical 




The mean lifespan was increased at a middle dose of PHA-E (0.054 µM) from 17 days to 23 
days (39%, P<0.05), which was blocked by GalNAc, and was reduced at a higher dose (0.17 µM) from 
11 days to 8 days (-28%, P<0.05) in presence of SIS.  GalNAc (1.58 mM) only reduced the mean 
lifespan from 17 days to 11 days (-34%, P<0.05, Figure 29e).  
 
 
Figure 29. PHA-E-rhodamine did not show co-localization with DAergic neurons in liquid culture but 
affected the DAergic neurons.  A) Number of DAergic neurons was reduced at the highest dose (0.17 
µM) with the SIS present.  B) The fluorescence intensity of GFP-DAergic neurons was increased dose-
dependently at all doses (0.017 µM, 0.054 µM & 0.17 µM, P<0.05), which was blocked by the SIS at 
the highest dose (0.17 µM).  C) The average size of GFP-DAergic neurons was also reduced at the 
highest dose (0.17 µM, P<0.05), which was augmented by the presence of the SIS.  D) The APS was 
increased dose-dependently at lower doses, which was blocked by SIS GalNAc (1.58 mM), and was 
reduced by GalNAc only.  E) The mean lifespan was increased at a middle dose (0.054 µM) from 17 
days to 23 days (39%, P<0.05), which was blocked by GalNAc, and was reduced at a higher dose (0.17 
µM) from 11 days to 8 days (-28%, P<0.05) in presence of SIS.  GalNAc (1.58 mM) only reduced the 
mean lifespan from 17 days to 11 days (-34%, P<0.05).  * indicates statistical significance, # indicates 





Pisum Sativum agglutinin (PSA)-rhodamine did not show co-localization with GFP-DAergic 
neurons but affected the DAergic neurons. The number of DAergic neurons was not altered, but was 
reduced at the highest dose (0.43 µM, P<0.05) in presence of the SIS α-methylmannoside (200 mM) plus 
α-methylglucoside (200 mM, Figure 30a).  The intensity was diminished at the highest dose of PSA (0.43 
µM, P<0.05), which was eliminated in presence of the SIS (Figure 30b). 
 
 
Figure 30. PSA-rhodamine did not show co-localization with GFP-DAergic neurons but affected the GFP-
DAergic neurons in C. elegans.  A) The number of DAergic neurons was not altered, but was reduced at 
the highest dose (0.43 µM, P<0.05) in presence of the SIS α-methylmannoside (200 mM) plus α-
methylglucoside (200 mM).  B) The intensity was diminished at the highest dose (0.43 µM, P<0.05), 
which was eliminated in presence of the SIS.  C) The size was reduced at the lowest dose (0.043 µM, 
P<0.05), which was blocked by the SIS, and was increased it at middle dose (0.129 µM, P<0.05) with the 
SIS.  D) The APS was increased at all doses, which was blocked at the highest dose in presence of the SIS.  
E) The mean lifespan was increased by lower doses (0.043 µM & 0.43 µM) from 22 days to 27 days (22% 
& 23%, P<0.05), which was blocked by SIS at the highest dose (0.43 µM), and was increased at a lower 






The size was reduced at the lowest dose (0.043 µM, P<0.05), which was blocked by the SIS, and 
was increased it at medium dose (0.129 µM, P<0.05) with the SIS (Figure 30c).  The APS was increased 
at all doses of PSA, which was blocked at the highest dose in presence of the SIS (Figure 30d).  The mean 
lifespan was increased by lower doses (0.043 µM & 0.43 µM) from 22 days to 27 days (22% and 23%, 
P<0.05), which was blocked by SIS at the highest dose (0.43 µM), and was increased at a lower dose 
(0.043 µM) from 23 days to 28 days in presence of the SIS (21%, P<0.05, Figure 30e). 
Ulex Europaeus I (UEA I)-TRITC did not show co-localization with GFP-DAergic neurons but 
affected the DAergic neurons.  The number of DAergic neurons was not altered, but was increased at the 
highest dose (0.33 µM, P<0.05) in presence of the SIS L-fucose (50 mM, Figure 31a).  The intensity was 
diminished at all doses (0.033, 0.099 & 0.33 µM, P<0.05), which was eliminated in presence of the SIS 
(Figure 31b).  The size was reduced at all doses (0.033, 0.099 & 0.33 µM, P<0.05), which was blocked 
by the SIS, and was increased at the highest dose (0.33 µM, P<0.05) in presence of the SIS (Figure 31c).  
The APS was increased at the lowest dose, which was blocked by the SIS (Figure 31d).  The mean lifespan 
was increased by the lowest dose (0.033 µM) from 22 days to 25 days (13%, P<0.05), which was blocked 
by SIS, and was reduced at the highest dose (0.99 µM) from 21 days to 16 days in presence of the SIS 
(26%, P<0.05, Figure 31e). 
Triticum vulgaris agglutinin (WGA)-rhodamine was not detected as being transported to the 
DAergic neurons but affected the DAergic neurons.  The number of DAergic neurons was not altered 
(Figure 32a).  The intensity of the GFP-DAergic neurons was increased at the highest dose (0.46 µM, 
P<0.05), which was augmented in presence of the SIS (Figure 32b).  The area of the DAergic neurons was 
reduced at all doses (P<0.05), which was blocked by the SIS (Figure 32c).  The APS was increased at all 
doses, which was blocked by SIS (Figure 32d).  The mean lifespan was increased at the highest dose (0.46 





Figure 31. UEA I-TRITC did not show co-localization with GFP-DAergic neurons but affected the 
DAergic neurons.  A) The number of DAergic neurons was not altered, but was increased at the highest 
dose (0.33 µM, P<0.05) in presence of the SIS L-fucose (50 mM).  B) The intensity was diminished at all 
doses (0.033, 0.099 & 0.33 µM, P<0.05), which was eliminated in presence of the SIS.  C) The size was 
reduced at all doses (0.033, 0.099 & 0.33 µM, P<0.05), which was blocked by the SIS, and was increased 
at the highest dose (0.33 µM, P<0.05) in presence of the SIS.  D) The APS was increased at the low dose, 
which was blocked in presence of the SIS.  E) The mean lifespan was increased by low dose (0.033 µM) 
from 22 days to 25 days (13%, P<0.05), which was blocked by SIS, and was reduced at the highest dose 
(0.99 µM) from 21 days to 16 days in presence of the SIS (26%, P<0.05).  * indicates statistical 
significance.  
 
Lens culinaris (LcH)-TRITC was not detected as transported to but affected DAergic neurons.  
The number of DAergic neurons was increased at low and high doses (0.05 µM & 0.5 µM, P<0.05), which 
was blocked at low dose and reversed at high does (0.5 µM, P<0.05, Figure 33a).  The intensity of the 
GFP-DAergic neurons was increased at the lowest dose (0.05 µM, P<0.05), which was reversed in the 
presence of the SIS.  Besides, the intensity was reduced at higher doses (0.05 µM & 0.15 µM, P<0.05) in 




reduced by the highest dose (0.5 µM, P<0.05) in presence of the SIS (Figure 33c).   The APS was increased 
at the lowest dose and reduced at the highest dose, which was enhanced by the SIS (Figure 33d).  The 
mean lifespan was increased at the lowest dose (0.05 µM) from 18 days to 23 days (27%, P<0.05) which 
was blocked by the SIS, and decreased at the highest dose (0.5 µM) to 12 days (-37%, P<0.05) which was 
enhanced in presence of the SIS.  The mean lifespan was increased by the SIS only from 18 days to 27 
days (45%, P<0.05, Figure 33e). 
 
 
Figure 32. WGA-rhodamine affected the intensity and area of DAergic neurons.  A) The number of 
DAergic neurons was not altered by WGA with or without the SIS chitin hydrolysate (2.5%).  B) The 
intensity of the GFP-DAergic neurons was increased at the highest dose (0.46 µM, P<0.05), which was 
augmented in the presence of the SIS.  C) The area of the DAergic neurons was reduced at all doses 
(P<0.05), which was blocked by the SIS.  D) The APS was increased at all doses, which was blocked by 
the SIS.  E) The mean lifespan was increased at the highest dose (0.46 µM) from 20 days to 24 days (22%, 





Figure 33. LcH-TRITC was not detected as transported to but affected DAergic neurons.  A) The number 
of DAergic neurons was increased at low and high doses (0.05 µM & 0.5 µM, P<0.05), which was blocked 
at low dose and reversed at high does (0.5 µM, P<0.05).  B) The intensity of the GFP-DAergic neurons 
was increased at the lowest dose (0.05 µM, P<0.05), which was reversed in the presence of the SIS.  
Besides, the intensity was reduced at higher doses (0.05 µM & 0.15 µM, P<0.05) in presence of the SIS.  
C) The area of the DAergic neurons was not altered (P>0.05), which was reduced by the highest dose (0.5 
µM, P<0.05) in presence of the SIS.  D) The APS was increased at the lowest dose and reduced at the 
highest dose, which was enhanced by the SIS.  E) The mean lifespan was increased at the lowest dose 
(0.05 µM) from 18 days to 23 days (27%, P<0.05) which was blocked by the SIS, and decreased at the 
highest dose (0.5 µM) to 12 days (37%, P<0.05) which was enhanced in presence of the SIS.  The mean 
lifespan was increased by the SIS only from 18 days to 27 days (45%, P<0.05).  * indicates statistical 
significance, # indicates SIS plus OP50 vs. OP50 only. 
 
Triticum vulgaris (Succinylated) S-WGA-rhodamine did not show co-localization but affected 
DAergic neurons in C. elegans.  The number of the GFP-DAergic neurons was decreased at lower doses 
(0.046 µM & 0.138 µM, P<0.05), which was blocked by the SIS chitin hydrolysate (2.5%, Figure 34a).  
The fluorescent intensity of GFP-DAergic neurons was increased at all doses (0.046 µM, 0.138 µM & 




the highest dose (0.46 µM, P<0.05, Figure 34b).  The size of GFP-DAergic neurons was decreased at all 
doses (0.046 µM, 0.138 µM & 0.46 µM, P<0.05), which was blocked by the SIS (Figure 34c).   
 
 
Figure 34. S-WGA-rhodamine affected GFP-DAergic neurons in C. elegans.  A) The number of the GFP-
DAergic neurons was decreased at lower doses (0.046 µM & 0.138 µM, P<0.05), which was blocked by 
the SIS chitin hydrolysate (2.5%).  B) The fluorescent intensity of GFP-DAergic neurons was increased 
at all doses (0.046 µM, 0.138 µM & 0.46 µM, P<0.05), which was blocked by the SIS at medium dose 
(0.138 µM, P>0.05) and reversed by the highest dose (0.46 µM, P<0.05).  C) The size of GFP-DAergic 
neurons was decreased at all doses (0.046 µM, 0.138 µM & 0.46 µM, P<0.05), which was blocked by the 
SIS.  D) The APS was increased at a low dose, and decreased does-dependently at higher doses, which 
was blocked by SIS.  E) The mean lifespan was increased at the lowest dose (0.138 µM) from 21 days to 
23 days (9%, P<0.05), and decreased at the highest dose (0.46 µM) to 12 days (-43%, P<0.05), which was 
blocked by the SIS at all doses.  The mean lifespan was reduced by the SIS only from 21 days to 14 days 
(-33%, P<0.05).  * indicates statistical significance, # indicates SIS plus OP50 vs. OP50 only. 
 
The APS was increased at a low dose, and decreased at higher doses, which was blocked by SIS 
(Figure 34d).  The mean lifespan was increased at the lowest dose (0.138 µM) from 21 days to 23 days 




by the SIS at all doses.  The mean lifespan was reduced by the SIS only from 21 days to 14 days (-33%, 
P<0.05, Figure 34e). 
Artocarpus integrifolia agglutinin (AIA)-TRITC did not show co-localization and did not affect 
DAergic neurons in C. elegans.  The number of the GFP-DAergic neurons was not altered by AIA, with 
or without the SIS galactose (32 mM, P>0.05, Figure 35a).   
 
Figure 35. AIA-TRITC did not show co-localization and did not affect DAergic neurons in C. elegans.  
A) The number of the GFP-DAergic neurons was not altered by AIA, with or without the SIS galactose 
(32 mM, P>0.05).  B) The fluorescent intensity of GFP-DAergic neurons was not altered by AIA (P>0.05).  
C) The size of GFP-DAergic neurons was not altered by AIA (P>0.05).  D) The APS was decreased at all 
doses, which was enhanced by the SIS.  E) The mean lifespan was increased at all doses (0.046 µM, 0.138 
µM & 0.46 µM) from 24 days to 15 days, 13 days and 11 days (-36%, -47% & -56%, P<0.05), which was 
blocked at the lowest dose (0.046 µM) in presence of the SIS.  The mean lifespan was reduced by the SIS 
only from 24 days to 15 days (-37%, P<0.05).  * indicates statistical significance, # indicates SIS plus 
OP50 vs. OP50 only. 
 
The fluorescent intensity of GFP-DAergic neurons was not altered by AIA (P>0.05, Figure 35b).  




at all doses, which was enhanced by the SIS (Figure 35d).  The mean lifespan was increased at all doses 
(0.046 µM, 0.138 µM & 0.46 µM) from 24 days to 15 days, 13 days and 11 days (-36%, -47% & -56%, 
P<0.05), which was blocked at the lowest dose (0.046 µM) in presence of the SIS.  The mean lifespan 
was reduced by the SIS only from 24 days to 15 days (-37%, P<0.05, Figure 35e). 
Cytisus scoparius agglutinin (CSA)-TRITC did not show co-localization but affected DAergic 
neurons in C. elegans.  The number of the GFP-DAergic neurons was reduced at the highest dose (0.65 
µM, P<0.05), which was blocked by the SIS GalNAc 20 mM (Figure 36a).   
 
Figure 36. CSA-TRITC did not show co-localization but affected DAergic neurons in C. elegans.  A) The 
number of the GFP-DAergic neurons was reduced at the highest dose (0.65 µM, P<0.05), which was 
blocked by the SIS GalNAc 20 mM.  B) The fluorescent intensity of GFP-DAergic neurons was not altered 
at all doses (P>0.05), which was reduced at high doses (0.195 µM & 0.65 µM, P<0.05) in presence of the 
SIS.  C) The size of GFP-DAergic neurons was increased at all doses (0.065 µM, 0.195 µM & 0.65 µM, 
P<0.05), which was blocked in presence of the SIS.  D) The APS was decreased at the highest dose, which 
was blocked by the SIS.  E) The mean lifespan was reduced at the highest dose (0.65 µM) from 18 days 
to 14 days (-22%, P<0.05), which was blocked in presence of the SIS.  The mean lifespan was reduced by 
the SIS only from 18 days to 14 days (-24%, P<0.05).  * indicates statistical significance, # indicates SIS 




The fluorescent intensity of GFP-DAergic neurons was not altered at all doses (P>0.05), which 
was reduced at high doses (0.195 µM & 0.65 µM, P<0.05) in presence of the SIS (Figure 36b).  The size 
of GFP-DAergic neurons was increased at all doses (0.065 µM, 0.195 µM & 0.65 µM, P<0.05), which 
was blocked in presence of the SIS (Figure 36c).  The APS was decreased at the highest dose, which was 
blocked by the SIS (Figure 36d).  The mean lifespan was reduced at the highest dose (0.65 µM) from 18 
days to 14 days (-22%, P<0.05), which was blocked in presence of the SIS.  The mean lifespan was reduced 
by the SIS only from 18 days to 14 days (-24%, P<0.05, Figure 36e). 
Dolichos biflorus agglutinin (DBA)-rhodamine did not show co-localization with GFP-DAergic 
neurons but affected the DAergic neurons.  The number of DAergic neurons was not altered, but was 
increased at the highest dose (0.18 µM, P<0.05) in presence of the SIS GalNAc (50 mM, Figure 37a).  
The fluorescence intensity of GFP-DAergic neurons was increased at the lowest dose (0.018 µM, P<0.05), 
which was reversed by the SIS, and was increased at higher doses (0.054 µM & 0.18 µM, P<0.05) in 
presence of the SIS (Figure 37b).  The size of GFP-DAergic neurons was increased in a dose-dependent 
trend at all doses (0.018 µM, 0.054 µM & 0.18 µM, P<0.05), which was blocked by the SIS (Figure 37c).  
The APS was increased by lower doses of DBA, and decreased by higher doses (Figure 37d).  The mean 
lifespan was reduced at the highest dose (0.18 µM) from 19 days to 11 days (-43%, P<0.05).  The animals 
did not survive in presence of GalNAc (50 mM) within two days, possibly because of UDP depletion 
(Figure 37e). 
Galanthus nivalis agglutinin (GNA)-rhodamine did not show co-localization with GFP-DAergic 
neurons or affect the DAergic neurons.  The number of DAergic neurons was not altered with or without 
the SIS mannose (34 mM, Figure 38a).  The fluorescence intensity of GFP-DAergic neurons was not 
altered at all doses, which was reduced at the medium dose (0.231 µM, P<0.05) in presence of the SIS 





Figure 37. DBA-TRITC did show co-localization but affected the DAergic neurons in C. elegans. A) The 
number of DAergic neurons was not altered, but was increased at the highest dose (0.18 µM, P<0.05) in 
presence of the SIS GalNAc (50 mM).  B) The fluorescence intensity of GFP-DAergic neurons was 
increased at the lowest dose (0.018 µM, P<0.05), which was reversed by the SIS, and was increased at 
higher doses (0.054 µM & 0.18 µM, P<0.05) in presence of the SIS.  C) The size of GFP-DAergic neurons 
was increased in a dose-dependent trend at all doses (0.018 µM, 0.054 µM & 0.18 µM, P<0.05), which 
was blocked by the SIS.  D) The APS was increased at lower dose, and decreased at higher doses.  E) The 
mean lifespan was reduced at the highest dose (0.18 µM) from 19 days to 11 days (-43%, P<0.05).  The 
animals did not survive in presence of GalNAc (50 mM) within two days.  * indicates statistical 
significance, # indicates SIS plus OP50 vs. OP50 only. 
 
The size of GFP-DAergic neurons was increased at all doses (0.077 µM, 0.231 µM & 0.77 µM, 
P<0.05), which was blocked by the SIS (Figure 38c).  The APS was reduced at all doses, which was 
enhanced by the SIS (Figure 38d).  The mean lifespan was reduced at higher doses (0.077 µM & 0.231 
µM) from 24 days to 20 days and 19 days (-16% & -23%, P<0.05), which was enhanced in presence of 






Figure 38. Galanthus nivalis agglutinin (GNA)-rhodamine did not show co-localization with GFP-
DAergic neurons or affect the DAergic neurons.  A) The number of DAergic neurons was not altered with 
or without the SIS mannose (34 Mm).  B) The fluorescence intensity of GFP-DAergic neurons was not 
altered at all doses, which was reduced at the medium dose (0.231 µM, P<0.05) in presence of the SIS.  
C) The size of GFP-DAergic neurons was increased at all doses (0.077 µM, 0.231 µM & 0.77 µM, P<0.05), 
which was blocked by the SIS.  D) The APS was reduced at all doses, which was enhanced by the SIS.  E) 
The mean lifespan was reduced at higher doses (0.077 µM & 0.231 µM) from 24 days to 20 days and 19 
days (-16% & -23%, P<0.05), which was enhanced in presence of the SIS.  * indicates statistical 
significance.  * indicates statistical significance. 
 
Griffonia Simplicifolia (GSL I)-TRITC did show co-localization but affected the DAergic neurons 
in C. elegans.  The number of the GFP-DAergic neurons was not altered (Figure 39a).  The fluorescence 
intensity of GFP-dopamine transporter protein in DAergic neurons was dose-dependently increased at all 
doses (0.018 µM, 0.054 µM & 0.18 µM, P<0.05), which was augmented at lower doses (0.018 µM & 
0.054 µM, P<0.05) and mitigated at the highest dose (0.18 µM, P<0.05, Figure 39b) by the SIS galactose 
(40 mM).  The size of GFP-DAergic neurons was not altered, but was dose-dependently increased at all 




dependently decreased at all doses, which was reversed by SIS (Figure 39d).  The mean lifespan was 
decreased at the highest dose (0.18 µM) from 17 days to 10 days (-37%, P<0.05), which was blocked by 
the SIS (Figure 39e). 
 
 
Figure 39. GSL I-TRITC did show co-localization but affected the DAergic neurons in C. elegans. A) The 
number of the GFP-DAergic neurons was not altered.  B) The fluorescence intensity of GFP-dopamine 
transporter protein in DAergic neurons was dose-dependently increased at all doses (0.018 µM, 0.054 µM 
& 0.18 µM, P<0.05), which was augmented at lower doses (0.018 µM & 0.054 µM, P<0.05) and mitigated 
at the highest dose (0.18 µM, P<0.05) by the SIS galactose (40 mM).  C) The size of GFP-DAergic neurons 
was not altered, but was dose-dependently increased at all doses (0.018 µM, 0.054 µM & 0.18 µM, P<0.05) 
in presence of the SIS.  D) The APS was dose-dependently decreased at all doses, which was blocked by 
SIS.  E) The mean lifespan was decreased at the highest dose (0.18 µM) from 17 days to 10 days (-37%, 
P<0.05), which was blocked by the SIS.  *indicates statistical significance. 
 
Hippeastrum hybrid agglutinin (HHA)-TRITC did show co-localization but affected the DAergic 
neurons in C. elegans.  The number of the GFP-DAergic neurons was not altered with or without the SIS 
mannose (10 mM, Figure 40a).  The fluorescence intensity of GFP-dopamine transporter protein in 




at lower doses (0.04 µM & 0.12 µM, P>0.05) and reversed at the highest dose (0.2 µM, P<0.05) in 
presence of the SIS (Figure 40b).   
 
 
Figure 40. HHA-TRITC did show co-localization but affected the DAergic neurons in C. elegans.  A) The 
number of the GFP-DAergic neurons was not altered with or without the SIS mannose (10 mM).  B) The 
fluorescence intensity of GFP-dopamine transporter protein in DAergic neurons was increased at all doses 
(0.04 µM, 0.12 µM & 0.4 µM, P<0.05), which was blocked at lower doses (0.04 µM & 0.12 µM, P>0.05) 
and reversed at the highest dose (0.2 µM, P<0.05) in presence of the SIS.  C) The size of GFP-DAergic 
neurons was increased at the lowest dose (0.04 µM, P<0.05), which was reversed in presence of the SIS 
and reduced at the highest dose (0.4 µM, P<0.05) in presence of the SIS.  D) The APS was dose-
dependently decreased at all doses.  E) The mean lifespan was decreased at higher doses (0.12 µM& 0.4 
µM) from 21 days to 15 days and 11 days (-29% & -47%, P<0.05), which was blocked at the medium 
dose (0.12 µM) in presence of the SIS.  * indicates statistical significance. 
 
The size of GFP-DAergic neurons was increased at the lowest dose of HHA (0.04 µM, P<0.05), 
which was reversed in presence of the SIS and reduced at the highest dose (0.4 µM, P<0.05) in presence 
of the SIS (Figure 40c).  The APS was dose-dependently decreased at all doses (Figure 40d).  The mean 




& -47%, P<0.05), which was blocked at the medium dose (0.12 µM) in presence of the SIS (Figure 40e). 
Phaseolus vulgaris agglutinin-L (PHA-L)-TRITC did show co-localization but affected the 
DAergic neurons in C. elegans.  The number of the GFP-DAergic neurons was not altered with or without 
the SIS GalNAc (1.58 mM, Figure 40a).  The fluorescence intensity of GFP-dopamine transporter protein 
in DAergic neurons was reduced at lower doses (0.017 µM & 0.051 µM, P<0.05), which was reduced at 
the highest dose (0.17 µM, P<0.05) in presence of the SIS (Figure 40b). 
 
 
Figure 41. PHA-L-TRITC did show co-localization but affected the DAergic neurons in C. elegans.  A) 
The number of the GFP-DAergic neurons was not altered with or without the SIS GalNAc (1.58 mM).  B) 
The fluorescence intensity of GFP-dopamine transporter protein in DAergic neurons was reduced at lower 
doses (0.017 µM & 0.051 µM, P<0.05), which was reduced at the highest dose (0.17 µM, P<0.05) in 
presence of the SIS.  C) The size of GFP-DAergic neurons was increased at all doses (0.017 µM, 0.051 
µM & 0.17 µM, P<0.05), which was blocked at the highest dose (0.17 µM) in presence of the SIS.  D) 
The APS was increased at low dose and reduced at higher doses.  E) The mean lifespan was reduced at 
the highest dose (0.17 µM) from 20 days to 13 days (-34%, P<0.05), which was increased at the lowest 
dose (0.017 µM) in presence of the SIS.  * indicates statistical significance. 




P<0.05), which was blocked at the highest dose (0.17 µM) in presence of the SIS (Figure 40c).  The APS 
was increased at low dose and reduced at higher doses (Figure 40d).  The mean lifespan was reduced at 
the highest dose (0.17 µM) from 20 days to 13 days (-34%, P<0.05), which was increased at the lowest 
dose (0.017 µM) in presence of the SIS (Figure 40e). 
Soybean agglutinin (SBA)-TRITC did show co-localization but affected the DAergic neurons in 
C. elegans (Figure 42).   
 
Figure 42. Soybean agglutinin (SBA)-TRITC did show co-localization but affected the DAergic neurons 
in C. elegans.  A) The number of the GFP-DAergic neurons was decreased at the lowest dose (0.017 µM, 
P<0.05), which was blocked by the SIS GalNAc (12.5 mM).  B) The intensity of DAergic neurons was 
not altered at all doses (P>0.05), which was increased at the lowest dose (0.017 µM, P<0.05) and reduced 
at the highest dose (0.17 µM, P<0.05) in presence of the SIS.  C) The size of GFP-DAergic neurons was 
reduced at the lowest dose (0.017 µM, P<0.05), which was blocked in the presence of the SIS.  D) The 
APS was slightly increased at low doses and reduced at higher dose.  E) The mean lifespan was reduced 
at the highest dose (0.17 µM) from 20 days to 14 days (-31%, P<0.05), which was blocked by the SIS.  
The mean lifespan was reduced by the SIS only from 20 days to 11 days (-48%, P<0.05).  * indicates 





The number of the GFP-DAergic neurons was decreased at the lowest dose (0.017 µM, P<0.05), 
which was blocked by the SIS GalNAc (12.5 mM, Figure 42a).  The fluorescence intensity of GFP-
dopamine transporter protein in DAergic neurons was not altered at all doses (P>0.05), which was 
increased at the lowest dose (0.017 µM, P<0.05) and reduced at the highest dose (0.17 µM, P<0.05) in 
presence of the SIS (Figure 42b).  The size of GFP-DAergic neurons was reduced at the lowest dose (0.017 
µM, P<0.05), which was blocked in the presence of the SIS (Figure 42c).  The APS was slightly increased 
at low doses and reduced at higher dose (Figure 42d).  The mean lifespan was reduced at the highest dose 
(0.17 µM) from 20 days to 14 days (-31%, P<0.05), which was blocked by the SIS.  The mean lifespan 
was reduced by the SIS only from 20 days to 11 days (-48%, P<0.05, Figure 42e).  
Concanavalin A (Con A)-TRITC did not show co-localization with but affected GFP-DAergic 
neurons in C. elegans.  The number of DAergic neurons was not altered with or without the SIS α-
methylmannoside (200 mM) plus α-methylglucoside (200 Mm, Figure 43a).  The fluorescence intensity 
of GFP-dopamine transporter protein image in DAergic neurons was increased at the highest dose (0.19 
µM, P<0.05) and reversed by the SIS (P<0.05, Figure 43b).  The size was reduced at middle dose (0.057 
µM, P<0.05), which was blocked by the SIS (Figure 43c).  The APS was increased at all doses, which 
was blocked by the SIS (Figure 43d).  The mean lifespan was not altered with or without SIS (Figure 43e). 
Cicer arietinum agglutinin (CPA)-TRITC did not show co-localization with but affected GFP-
DAergic neurons in C. elegans.  The number of DAergic neurons was not altered with or without the SIS 
bovine fetuin (0.77 µM, Figure 44a).  The fluorescence intensity of GFP-dopamine transporter protein 
image in DAergic neurons was reduced at the doses (0.047 µM & 0.47 µM, P<0.05), which was blocked 
at the lowest dose (0.047 µM) by the SIS (Figure 44b).  The size was reduced at middle at the doses (0.047 
µM & 0.47 µM, P<0.05), which was blocked by the SIS (Figure 44c).  The APS was increased at all doses, 
which was reversed by the SIS (Figure 44d).  The mean lifespan was not altered by CPA, which was 




The mean lifespan was increased by the SIS only from 23 days to 29 days (28%, P<0.05, Figure 44e). 
 
Figure 43. Con A-rhodamine affected the GFP-DAergic neurons in C. elegans.  A) The number of 
DAergic neurons was not altered with or without the SIS α-methylmannoside (200 mM) plus α-
methylglucoside (200 Mm).  B) The fluorescence intensity of GFP-dopamine transporter protein image 
in DAergic neurons was increased at the highest dose (0.19 µM, P<0.05) and reversed by the SIS (P<0.05).  
C) The size was reduced at middle dose (0.057 µM, P<0.05), which was blocked by the SIS.  D) The APS 
was increased at all doses, which was blocked by the SIS.  E) The mean lifespan was not altered with or 
without SIS.  * indicates statistical significance. 
 
Solanum tuberosum agglutinin (STA)-TRITC did not show co-localization with but affected GFP-
DAergic neurons in C. elegans.  The number of DAergic neurons was not altered with or without the SIS 
chitin hydrolystate (2.5%, Figure 45a).  The fluorescence intensity of GFP-dopamine transporter protein 
image in DAergic neurons was not altered (Figure 45b).   
The size was reduced at all doses of STA (0.02 µM, 0.06 µM & 0.2 µM, P<0.05), which was 




lifespan was not altered by STA.  The animals died within one week of adding treatments.  The mean 
lifespan was decreased by the SIS only from 22 days to 10 days (-54%, P<0.05, Figure 45e). 
 
Figure 44. CPA-TRITC did not show co-localization with but affected GFP-DAergic neurons in C. 
elegans.  A) The number of DAergic neurons was not altered with or without the SIS bovine fetuin (0.77 
µM).  B) The fluorescence intensity of GFP-dopamine transporter protein image in DAergic neurons was 
reduced at the doses (0.047 µM & 0.47 µM, P<0.05), which was blocked at the lowest dose (0.047 µM) 
by the SIS.  C) The size was reduced at middle at the doses (0.047 µM & 0.47 µM, P<0.05), which was 
blocked by the SIS.  D) The APS was increased at all doses, which was reversed by the SIS.  E) The mean 
lifespan was not altered by CPA, which was decreased by CPA from 29 days to 22 days and 11 days (-
25% & -64%, P<0.05) in presence of the SIS.  The mean lifespan was increased by the SIS only from 23 







Figure 45. STA-TRITC did not show co-localization with but affected GFP-DAergic neurons in C. elegans.  
A) The number of DAergic neurons was not altered with or without the SIS chitin hydrolystate (2.5%).  
B) The fluorescence intensity of GFP-dopamine transporter protein image in DAergic neurons was not 
altered.  C) The size was reduced at all doses (0.02 µM, 0.06 µM & 0.2 µM, P<0.05), which was blocked 
by the SIS.  D) The APS was slightly increased without the SIS.  E) The mean lifespan was not altered by 
STA.  The animals died within one week of adding treatments.  The mean lifespan was decreased by the 
SIS only from 22 days to 10 days (-54%, P<0.05).  * indicates statistical significance, # indicates SIS plus 
OP50 vs. OP50 only. 
 
1.4 Discussion 
The purpose of the specific inhibiting sugar was to bind with, and then block the corresponding 
lectins.  As stated in the beginning of this chapter, using high concentration of sugars would cause various 
other effects other than binding with lectins in the C. elegans organism, like UDP depletion causing the 
ceasing of RNA synthesis.  In the current study, SIS was observed to have various effects when 





The interaction between lectins and specific sugars is complicated, depending on properties of the 
sugar-binding sites in lectins and the moieties in the sugars.  Lectins have several sugar-binding sites 
available due to the repeat of sequences, some lectins like EEA and PNA bind to monosaccharide, other 
lectins like ACA and CSA bind to polysaccharides.  The sequence of amino acids in the sugar-binding 
sites of the lectins has an important role in selecting the specific sugars [16].  The binding between lectins 
and simple sugars is not as strong as between lectins and polysaccharides, but the multiple binding sites 
in simple sugars produce multivalent bindings with lectins [17], which increases the affinity of simple 
sugars and lectins to some extent.  The dissociation constant of lectin Con A from glycoprotein asialofetuin 
increases as the concentration of inhibiting sugars increases [18], which suggest that the binding between 
the sugars and lectins is reversible; the existence of the third compound may compete with sugars for the 
binding with lectins. 
1.4.1 SIS inhibited the effects of lectins on GFP-DAergic neurons or mean lifespan 
SIS were observed to block the effects caused by lectins on the GFP-DAergic neurons or mean 
lifespan.  The possible explanation is that the sugar binding sites of lectins were covered by the SIS first, 
which prevented the binding of lectins with other receptors on cell surface in C. elegans organism.  The 
effect of ACA (0.096 µM) on reducing the size of GFP-DAergic neurons was blocked by the SIS GalNAc, 
which might be due to the binding of SIS with ACA.  The observation that the SIS GalNAc did not block 
the effects of the highest dose of ACA (0.32 µM) might suggest the concentration of the SIS was not high 
enough to bind to all sugar binding sites of ACA.  Similarly, the SIS GalNAc only blocked the effects of 
lowest dose of ACA (0.032 µM) on reducing the mean lifespan but not on higher doses. 
1.4.2 SIS mitigated the effects of lectins on GFP-DAergic neurons or mean lifespan 
Some SIS were observed to alleviate the effects of lectins in C. elegans.  The reason that the SIS did 
not block the effect but only mitigated the effects might be due to the partial binding of the SIS with sugar 




the adding of the SIS lactose did not block these effects but only reduced the magnitude.  The effect of 
medium dose of EEA (0.136 µM) on reducing the mean lifespan was mitigated by the SIS. 
1.4.3 SIS affected the effects of lectins on GFP-DAergic neurons or mean lifespan 
SIS were also observed to enhance or the effects of SIS on lectins in C. elegans.  Lower doses of 
GSL I (0.018 & 0.054 µM) increased the fluorescence intensity of GFP-dopamine transporter protein 
image in DAergic neurons, with the SIS galactose present, these effects of increasing was strengthened.  
In addition, the SIS reversed the effect of the highest dose of Con A on increasing the fluorescence 
intensity of GFP-dopamine transporter protein image in DAergic neurons.  These findings were not caused 
by the effects of lectins only; the possible explanation might be due to some unknown effects caused by 
the SIS or the interactions between the SIS and lectins.  
The fact that only certain doses reduced the number of DAergic neurons but other doses did not 
suggests that this effect is dose-related.  The presence of lactose (10 mM) blocked this effect probably 
because lactose bound with the binding sites of EEA, thus reduced the activity of EEA.  In contrast to 
EEA, low doses of S-WGA reduced the number of DAergic neurons while the highest dose did not.  
Similarly, this effect was blocked by the presence of the SIS chitin hydrolysate (2.5%), probably due to 
the same mechanism as EEA.  The effects of CSA and SBA on reducing the number of DAergic neurons 
were also blocked by their SISs.  The reduction of neuron numbers indicated the toxicity of these lectins, 
which was consistent with the lifespan results, that both EEA and S-WGA reduced the mean lifespan 
significantly.  The lectin LcH increased the number of DAergic neurons at both the lowest dose and the 
highest dose.  These effects were either blocked at low dose or reversed at high dose by the SIS, which 
implied that high dose of the SIS had detrimental effects. 
The toxic effects of high concentration of sugars in C. elegans were expected, and lower 




that the SIS blocked the effects caused by lectins on GFP-DAergic neurons or mean lifespan, whereas, 
other effects might be due to the toxic effects of the SIS. 
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CHAPTER IV.  DIETARY BIOACTIVE COMPOUNDS MAY AFFECT LIFESPAN AND 
FAT STORAGE ASPECTS IN C. ELEGANS 
 
1.1 Introduction 
Health determines human lifespan as well as optimal quality of life [1, 2].  Aging at the cellular level 
involves complex interacting mechanisms that lead to functional declines which become manifest 
following birth and proceed through life.  A U.S. population based study demonstrated that mortality risk 
was directly correlated with body mass index (BMI).  Thus, above 25 kg/m2, BMI inversely correlated 
with lifespan [3].  The increasing age of western societies creates a greater burden of chronic diseases 
including cancer, cardiovascular disease, diabetes, and neurodegenerative disorders including PD and 
Alzheimer's disease [4-8], leading to a high cost of health care and a great financial burden to the public 
health system and families [9, 10].  Among complex factors, both obesity and aging decrease insulin 
sensitivity, impair the immune response, increase inflammation, impair the gut-bloodstream barrier, and 
decrease physical mobility [11].  Many dietary interventions provide noninvasive approaches to reinforce 
optimal nutrition, fight metabolic dysfunction, enhance physiological function, and promote a healthy 
lifespan [12-14]. 
Dietary polyphenol antioxidants play important roles in health [15-19].  Pomegranates (Punica 
granatum L.) have a high content of polyphenols (1.5%), including ellagic acid (EA), gallic acid, 
anthocynidins, flavan-3-ols, straight chain fatty acids, citric acid, and malic acid.  Pomegranates consist 
of about 80% of juice and 20% of seeds with water (85%), and 10% sugars consisting primarily of fructose 
(2.5 g to 17.6 g/100ml) [20, 21] (Table 6).  PJ has been shown to extend lifespan in mice [22, 23] and 
Drosophila melanogaster [24].  PJ extract (POMx) potentiates lifespan extension with dietary restriction, 
a finding attributed by polyphenols [22, 23].  POMx and PJ can also act as prebiotics, having demonstrated 
antibacterial properties in vitro, and can block DNA repair and inhibit proliferation of breast cancer cells 




androgen-synthesizing genes to induce apoptosis of human prostate cells (kappaB-dependent) in vitro and 
in mice in vivo [30-33].  POMx and PJ decrease prostate specific antigen in humans after surgery or 
radiation [34, 35], inhibit tumor-associated angiogenesis in vitro and in vivo [34], suppress inflammatory 
cell signaling in colon cancer cells [36] (50 mg/L PJ, in vitro), improve memory [37] and improve 
fecundity in humans [24, 38-40].   
As the main bioactive component, EA is a measure of the quality of PJ extract products [39, 41, 42].  
EA in humans reaches a maximum plasma level in 1 hour (31.9 ng/ml), is eliminated within 4 hours [43] 
and exerts an antioxidant effect [44].   Urolithin acid (UA) is the main active metabolite of EA and is 
formed by the colonic microflora.  UA lasts longer in the human body than EA or other EA metabolites 
[26, 45], and has better bioavailability [46].  UA also suppresses colorectal, hepatic, and prostate cancers 
synergistically with EA in vitro and in mice in vivo [47-51].  
Table 6. Nutrition facts of pomegranate juice 
Serving size 8 fl. oz. (236 mL)  
Amounts per serving  
Calories 150 
Calories from Fat 0 
% Daily Value 
Total Fat 0 g 0% 
  Saturated Fat 0 g 0% 
  Trans Fat 0 g  
Cholesterol l0 mg  
Sodium 0 mg 0% 
Potassium 600 mg 17% 
Total Carbohydrate 36 g 12% 
  Fiber 0 g 0% 
  Sugars 31 g  
Protein 1 g  
Vitamin A <2% 
Vitamin C <2% 
Calcium <2% 
Iron 0% 





C. elegans model organism is the first animal model to have its genome completely sequenced.  C. 
elegans conserves 65% of the genes associated with human diseases, and has been increasingly used for 
functional biomedical research with more than 300 transgenic and mutant strains available [52-62].  The 
C. elegans daf-16 gene, a homologue of the human gene FOXO, regulates C. elegans lifespan and 
mediates both lipid metabolism and insulin signaling pathways [63, 64].   
We hypothesized that pomegranate would increase lifespan while reducing intestinal fat deposition 
(IFD).  We evaluated four PJ products using the C. elegans wild type (N2) to assess their effect on lifespan 
and IFD, and to predict their potential effect on aging and obesity in humans.  In addition, we also used a 
daf-16 deficient mutant to assess the role of the FOXO signaling pathway in mediating the effects of 
botanicals evaluated. 
1.2 Materials and methods 
C. elegans strains wild type (N2) and daf-16 mutant (daf-16(mgDf50)I) GR1307, and their standard 
lab food, Escherichia coli (E. coli, OP50, Uracil auxotroph), were obtained from the Caenorhabditis 
Genetics Center (University of Minnesota, Minneapolis, MN).  PJ (POM Wonderful® LLC, Los Angeles, 
CA, USA) was purchased from a local grocery store.  POMx (extract of pomegranate) was a gift from 
POM Wonderful® LLC (Los Angeles, CA, USA).  EA was purchased from Sigma (St. Louis, MO, USA).  
UA was synthesized by Dr. David Heber’s laboratory [65]. 
1.2.1 Culture of C. elegans 
Mature gravid wild type C. elegans (N2, Bristol) and daf-16 deficient mutant [daf-16(mgDf50)I] 
were treated with NaOH (1M) and sodium hypochlorite solution (5.25%, 5:2 ratio) to dissolve the body 
and release viable eggs [61].  The eggs were hatched overnight after washing with S-complete solution 
three times.  The age-synchronized C. elegans were diluted to 100 animals/ml, plated in liquid culture in 




15C (daf-16 mutant) low temperature incubators (Revco Tech., Nashville, NC, USA).  Thirty microliters 
of 5-Fluoro-2′-deoxyuridine (FUDR, 0.6mM) stock solution was added to each well at Larvae 4 stage. 
1.2.2 Culture of Escherichia coli (E. coli, OP50) 
OP50 were cultured by the standard method described elsewhere [61].  Briefly, approximately 10 
µL of stock E. coli solution was added to media and incubated at 37°C for 24h.  The OP50 were then 
plated in PetrifilmTM (3M Corporate, St. Paul, MN) at 37°C for 24 h until densities of 5×108 to 5×1011 
colony forming units (cfu/ml) were reached and then were fed to the C. elegans ad libitum [61, 67].  The 
OP50 stock feeding solution was enriched to 2×109 cfu/ml by centrifuging at 2,200 g for 10 minutes and 
washed with S-complete buffer twice.     
1.2.3 Lifespan assays 
Fifty microliters of the treatments was added to each well three days after egg-synchronization.  The 
control group received OP50 only.  The experimental groups received additional PJ (0.01%, 0.1%, 1%, 
3%, 5%, 10% or 25%, v/v), POMx (5, 10, 20, 40, 80, 160, and 320 µg/ml), EA (1, 2, 5, 10, 25, and 50 µM 
in dimethyl sulfoxide (DMSO 0.05%), or UA (1, 2, 5, 10, 25, and 50 µM in DMSO) (n=10-15/well/6well).  
A second control (DMSO, 0.05%) was used in the EA and UA groups.  Additional OP50 was added to 
each well every other week until all animals were dead.  The numbers of live animals were manually 
recorded every other day under a microscope (Nikon, Eclipse Ti –S, Japan).  
1.2.4 Fluorescence microscopy 
Same treatments as in lifespan assay were added to each well at larvae 1 stage of animals.  Lipophilic 
dye, Nile red, was used to stain for IFD, and fluorescent intensity was evaluated [61].  C. elegans in each 
group were collected after 3 days of treatments, washed with S-Basal twice, fixed with paraformaldehyde 
(4%) over 2h at 4°C and washed with PBS for 5 min x 3.  Nile red (50 µL) was applied to the specimens 
for 10 min.  Ten microliters of Fluoromount-G (Southern Biotechnology Associates, Birmingham, AL) 




cover glass was mounted on the glass slide, and the slides were viewed with an epifluorescence 
microscope (Nikon Eclipse, Ti) equipped with a Texas Red filter.  Fluorescent micrographs were taken 
with a digital camera (Andor, DU-885k) and analyzed using Nikon-Elements (version 3.22.11).  Optical 
densities (arbitrary units) of Nile red stained IFD were determined for C. elegans (larvae 4). 
1.2.5 Statistical Analysis 
Analyses were carried out using SAS/STAT® software, Version 9.4 of the SAS System for 
Windows (Cary, NC, USA).  All results were expressed as mean±S.E.M.  Survival curves were displayed 
by binomial probabilities obtained from logistic regression models as surrogates for survival probabilities 
and mean lifespan was estimated via Kaplan-Meier (log-rank).  ANOVA models with post hoc Tukey 
adjustment were used to analyze fluorescence intensity data.  Statistical significance was defined as 
P<0.05. 
1.3 Results 
PJ treatment dose-dependently extended the mean lifespan of N2 up to 56% or daf-16 mutant up to 
30% in an A-shape curve, the magnitude of the lifespan extension was decreased at higher doses.  A 
similar trend with half the magnitude was observed in POMx treated animals in N2 (28%).  EA or UA did 
not significantly affect lifespan overall, however, lifespan extension was observed in several days of the 
experiment in each treatment (Supplement Table 8c & d).  The fluorescent intensity of IFD in C. elegans 
was reduced by PJ treatment in N2 (-68%) or in daf-16 (-33%).  In contrast, IFD was increased in N2 
more than in the daf-16 mutant by POMx (137% at 320 µg/ml vs. 26% at 20 µg/ml), or UA (57% at 10 





1.3.1 PJ dose-dependently extended then reduced lifespan in N2 and the daf-16 mutant  
In a dose-dependent manner, PJ added to the cultures significantly increased mean lifespan in N2 
up to the 1% dose but produced reduced lifespans at higher doses, an A-shape curve relationship (Figure 
46a & b).   
 
Figure 46. In an A-shape, PJ dose-dependently increased lifespan in both N2 (a & b) and daf-16 mutant 
(c & b) at lower doses, and dose-dependently reduced it at higher doses.  PJ dose-dependently reduced the 
fluorescent intensity of IFD (arbitrary unit) in N2 and daf-16 mutant (d). *P<0.05 
 
The average probability of survival across the lifespan was increased by lower doses of PJ (0.01%, 
0.1%, & 1%, P<0.05), while lifespan was decreased at higher doses (10% & 25%, P<0.05, Figure 46a).  
The mean lifespan was increased at lower doses (0.1% - 1%) from 21 to 33 days (42% - 56%, P<0.05) 
while it was decreased at higher doses (10% & 25%) from 33 to 4 days (-67% & -81%, P<0.05) (Figure 




manner up to 5 % after which survival was significantly reduced.  The dose-response curve shifted to the 
right.  The APS across the lifespan of the daf-16 mutant was increased at lower doses (1%, 3%, & 5%, 
P<0.05) and reduced at higher doses (10% & 25%, P<0.05, Figure 46c).  The mean lifespan of the daf-16 
mutant was increased from 27 to 32 days at a dose (5%) that reduced lifespan in N2 (18%, P<0.05) and 
decreased at the higher doses (-61% at 10% & -49% at 25%, P<0.05, Figure 46b).  Additionally, specific 
days during the experiment at which significant differences in survival probabilities were observed are 
provided (Supplement Table 8a).   
PJ dose-dependently reduced the fluorescent intensity of IFD in N2 and the daf-16 mutant (L4).  In 
N2, the IFD was reduced from 6971607 to 2372245 (-30% at 1%, -44% at 3%, -66% at 5%, -68% at 
10% & -55% at 25%, n=10, P<0.05).  The IFD was increased at lower doses in the daf-16 mutant from 
4677136 to 7222240 (54% at 0.01%, 28% at 0.1%, n=10, P<0.05), followed by reduction at higher 
doses to 3134252 (-24% at 1%, -21% at 5% & -33% at 25%, n=10, P<0.05) (Figure 46d). 
1.3.2 POMx dose-dependently increased lifespan in N2 and in the daf-16 mutant 
A dose-response curve for lifespan extension was also present in the N2 group treated with POMx, 
but was absent in the daf-16 mutant.  In N2, the APS across the lifespan was increased at all doses (5, 10, 
20, 40, 80, 160, & 320 µg/ml, P<0.05, Figure 47a). The mean lifespan was elevated from 18 to 22 days 
(18% at 10 μg/ml & 28% at 20 μg/ml, P<0.05, Figure 47b).  The APS across the lifespan of the daf-16 
mutant was increased at lower doses (5, 10, & 40 g/ml, P<0.05) and reduced at the highest dose (320 
g/ml, P<0.05, Figure 47c).  The mean lifespan of the daf-16 mutant was not altered (Figure 47b).  
Additionally, specific days during the experiment at which significant differences in survival probabilities 
were observed are provided (Supplement Table 8b).   
In N2, lower doses of POMx slightly reduced the IFD (P>0.05) followed by an increase from 




mutant, POMx increased the IFD from 5012±1032 to 6327±716 at mid-dose (26% at 20 µg/ml, n=10, 
P<0.05) followed by a reduction to 3815±736 at a higher dose (23.9% at 80 µg/ml, n=10, P<0.05) (Figure 
47d). 
 
Figure 47. An A-shape dose-responses of lifespan extension was present in POMx treated group in both 
N2 (a & b) and the daf-16 mutant (c & b), however, POMx was less potent than PJ.  In N2, had an initial 
elevation of life span in the presence of lower doses of POMx which also reduced the IFD (d).  IFD was 
increase at the highest dose.  In the daf-16 mutant, POMx increased IFD at mid-dose followed by a 
reduction at a higher dose. *P<0.05 
 
1.3.3 EA did not alter lifespan in N2 or in the daf-16 mutant 
Unlike PJ and POMx that increased lifespan dose-dependently, EA did not alter lifespan in N2 or 
the daf-16 mutant.  There was a mild increase of lifespan in N2 at lower doses and a mild decrease at 





Figure 48. EA did not alter lifespan in N2 (a & b) but increased the lifespan in the daf-16 mutant (c & b) 
at the highest dose.  The IFD (d) was dose-dependently elevated by EA in both N2 and daf-16 mutant, and 
the responses were in parallel with a greater elevation (by 2-fold) in the daf-16 mutant. *P<0.05 
 
The APS of the daf-16 mutant was elevated at the highest dose (50M, P<0.05, Figure 48c), but the 
increase in mean lifespan was not significant (P>0.05, Figure 48b).  The specific days during the 
experiment at which significant differences in survival probabilities were observed are provided 
(Supplement Table 8c).  The IFD elevation by EA was dose-dependent, similar in both N2 and the daf-16 
mutant, and in parallel with a 2-fold elevation in the daf-16 mutant.  In N2, EA increased IFD from 
5190±158 to 8608±323 at higher doses (66% at 5 µM, 59% at 10 µM, 58% at 25 µM, & 47% at 50 µM, 
n=10, P<0.05).  Similarly in the daf-16 mutant, EA increased IFD at the higher doses from 8237±227 to 





1.3.4 UA did not alter lifespan in N2 or in the daf-16 mutant 
As with EA, UA did not alter the lifespan in N2 or the daf-16 mutant.  In N2, the APS across the 
lifespan was increased at the highest dose (50 M, P<0.05, Figure 49a). 
 
Figure 49. The mean lifespan was increased in N2 (a & b) but decreased in daf-16 mutant (c & b) in UA 
treated group.  Animals treated with UA had an increased IFD (d) in both N2 and the daf-16 mutant with 
a parallel pattern of response with N2 showing a greater increase than the daf-16 mutant. *P<0.05 
 
The mean lifespan was not changed (P>0.05, Figure 49b).  The APS across the lifespan of the daf-
16 mutant was reduced at doses (1, 25, & 50 M, P<0.05, Figure 49c), while the mean lifespan was not 
changed (P>0.05, Figure 49b).  Additionally, specific days during the experiment at which significant 
differences in survival probabilities were observed are provided (Supplement Table 8d).  The IFD was 
increased in N2, from 1362±61 to 6278±991 in the DMSO-control group (361% at 0.05% DMSO, n=10, 




& 46% at 50 µM, n=10, P<0.05).  The IFD in the daf-16 mutant was increased from 3021±127 to 
4324±177 dose-dependently (34% at 10 µM & 43% at 50 µM, n=10, P<0.05) (Figure 49d).  
1.4 Discussion 
Our findings reveal that the lifespan extension has the same trend, either on a larger or on a smaller 
scale, in N2 and the daf-16 mutant by treatment with PJ or POMx, and with minimal effects on lifespan 
in cultures treated with EA or UA.  These results indicated that the daf-16 pathway was partially required 
for lifespan extension in the present study.  The survival curves displayed are approximated by estimated 
probabilities of survival across the lifespan (Binomial).  Although some treatment groups show 
statistically significant differences, comparisons based on these probabilities cannot be used to draw 
conclusions regarding lifespan.   
As energy sources, appropriate amount of sugar should have beneficial effects on lifespan 
extension.  However, high sugar (>2%) in the diet is detrimental to the C. elegans and reduces lifespan 
[62, 68-70].  The dose-response curves with an A-shape were seen in PJ and POMx treated animals.  We 
were puzzled by the fact that the lower doses of PJ increased lifespan, while the higher doses decreased 
the lifespan.  We wondered if this might be related to PJ’s high sugar content.  We found that the reversal 
of the lifespan extension by PJ was at a dose that contained 0.4% sugar (Table 7).  PJ has a high content 
of sugars in which the fructose is 1.25-fold greater than that of glucose which, in turn, is 4.7-fold higher 
than that of mannitol [71].  In agar dish culture, extra glucose (>0.001% or 2%) reduces lifespan mainly 
due to reducing signals of the DAF-16/FOXO and heat shock transcription factor (HSF-1) gene signaling 
[72-76].  The effect of fructose, however, is controversial.  Supplemental fructose reduces the plasma 
glucose level, glycohemoglobin, serum cholesterol, triglycerides, lactate, and body weight in type 2 
diabetes [75, 77].  Many epidemiological studies link the consumption of high dietary fructose usage to 
an increased prevalence of obesity, which has been reported with lack of sufficient evidence.  Since 




obesity [78-80].  The A-shape dose-response relationship with the lifespan in the present studies appears 
to be related to the increasing sugar content.  On the other hand, the level of sugar tolerance may be specie-
dependent, since a diet supplemented with PJ (10%) increase lifespan of flies [24].  The data also implies 
involvement of the daf-16 pathway, since the reduced lifespan was observed only at the highest dose in 
the daf-16 mutant group.  The A-shape curve of PJ showed the longest lifespan to be at a sugar content of 
0.13% in N2 and 0.66% in the daf-16 mutant.  The fact that PJ increased lifespan of the daf-16 mutant in 
our study may indicate alternative mechanism.  The lifespan curve shifting rightward might indicate an 
“independent or compensatory effect of the daf-16 pathway”.  
Table 7. Sugar content of the PJ feeding media 
Doses [%] 0 0.01 0.1 1 3 5 10 25 
Sugar [%] 0 0.001 0.013 0.13 0.39 0.66 1.31 3.28 
 
Fat storage is one of the outcomes of energy consumption and energy expenditure in living 
organisms.  In C. elegans, the fluorescent intensity of IFD in the PJ group was reduced in both N2 and the 
daf-16 mutant.  This inverse relationship of lifespan and fat content (PJ 1%) is in agreement with studies 
that PJ is effective in reducing cardiovascular risk factors in overweight humans [81].   
POMx, extracted from PJ, which is characterized by rich polyphenols extracted from pomegranate, 
extended the lifespan in a similar manner as PJ with an A-shape curve in N2.  POMx in the daf-16 mutant 
extended lifespan by several days (Supplement Table 8b).  Unlike PJ, POMx did not reduce lifespan at 
higher doses.  These results may be attributed to either an absent or reduced sugar content and/or other 
unknown factors.  The effect of POMx on lifespan extension was only half the magnitude of the lifespan 
extension induced by PJ, which suggests that multiple factors in the PJ products extend lifespan as was 
suggested by the Heber’s studies [82].  Also unlike PJ, a V-shape dose-response curve was detected for 
the IFD in POMx treated animals at the doses that were used in this study, and only a minimal reduction 




in IFD occurred at 80 g/ml, which seems to relate to the sugar content as it did in PJ treated group.  
Elevating IFD in the daf-16 mutant suggests the involvement of this pathway controlling body fat 
accumulation.    
Unlike either PJ or POMx, EA did not alter lifespan in N2 or in the daf-16 mutant at the doses that 
was used.  Lifespan extension was observed on several days of the experiment, which is similar with a 
study in N2 in agar culture that the EA (50 µM at 0.3% DMSO) prolonged mean lifespan [83].   
DMSO is a solvent that extends lifespan dose-dependently in N2 with an “A-shape ” curve, in agar 
culture (24% at 0.05% to 5%, v/v) [84] and in a liquid culture (20% at 0.9%, v/v) [85].  In the present 
study, DMSO doses were limited to the minimum.  The lower DMSO dose (0.05%) extended lifespan up 
to 12.7%, while the higher amount (0.1%) decreased the lifespan which is different from the observations 
of the Wang group [84], which observed a 30% reduction in lifespan in the daf-16 mutant (9.4%).  The 
effect of EA on extending lifespan suggested complex mechanisms involving daf-16 that is known as the 
gene for lifespan in C. elegans.  EA also dose-dependently increased IFD at higher doses in N2 with 
parallel findings in the daf-16 mutant.  The enhanced IFD in the daf-16 mutant uncovered the important 
role of the daf-16 on lipid/energy metabolism, which was not seen in the PJ treated groups. 
Like all polyphenols, EA’s large molecular weight and hydrophilic properties could have limited 
the absorption in the intestine as well as the bioavailability to the hosts.  Since the main metabolites of EA 
have many beneficial effects, the effects of UA which is a metabolite of the colonic microbiota that has a 
higher absorption index has attracted extensive research in recent years [86].  UA has anti-inflammatory, 
anti-carcinogenic, anti-glycative, anti-oxidant, and anti-microbial effects [86-88].  In our study, some of 
the treatment groups showed a statistically significant increase in mean survival probabilities in the 
presence of UA.  Although one cannot draw conclusions from these observations, it is possible that higher 
doses of UA may alter lifespan, and the daf-16 mutant pathway is predicted to mediate the effect of UA 




in parallel, with the latter having half the increase in IFD. 
The antioxidant potency of PJ is higher (by at least 20%) compared to other polyphenol-rich 
products including red wine, Concord grape juice, blueberry juice, black cherry juice, cranberry juice, 
orange juice, iced tea beverages, and apple juice in vitro [89].  Thus, PJ has superior antioxidant bioactivity 
compared to its purified polyphenols, EA, punicalagin, or total pomegranate tannin.  These conclusions 
are consistent with Seeram et al. who cited multifactorial effects and chemical synergy of the action of 
multiple compounds in PJ compared to single purified active ingredients [82].   
EA content varies by variety of the fruit, and many commercial pomegranate extracts were found 
not to contain the same amount of EA [42].  We used a commercially available PJ product [90-93], 
described in a full analysis of 477 commercial PJ in the market across North America and Asia [94].  
Although studies in humans the pharmacokinetics of EA and UA that are equivalent [65], our study 
showed, as previously reported, that PJ was the most potent in extending lifespan and reducing IFD with 
POMx being only half as potent.  The total phenolic content, by organic phenolic acid gallic acid 
equivalent (GAE), are 4.7-fold higher in PJ (2,825 µg/ml GAE) than in that of POMx (606 µg/mg GAE) 
[25].  In the present study, the estimated GAE (g/ml) by calculation was also directly related to the 
lifespan extension at lower doses by PJ or POMx, which was reduced by higher doses (supplement 
Table 9, Table 10 & Figure 50).  Thus, the fact that PJ was more potent than POMx may be beyond 
different amount of polyphenols but the synergy of various components rather than, for example, EA 
only [95].  The lower or lack of effect of other tested substances compared to PJ suggest that some 
effective compounds may be reduced or absent, and multifactorial effects were present.   
Our data from the C. elegans model indicate that the extension of lifespan by pomegranate is 
partially dependent on the daf-16 pathway, but mechanisms other than those involving polyphenols such 
as EA and its metabolites including UA may play a role as well.  The unique effects of PJ in reducing IFD 




provide useful information and suggest that, at the proper dilution, PJ may have optimal health benefits 
including control of fat storage, prevent obesity and offer a solution to delay aging in humans. 
 
Figure 50. The estimated GAE (g/ml) by calculation was also directly related to the lifespan extension 
at lower doses by PJ (black) or POMx (red) (a).  The correlation of estimated GAE with lower doses of 
PJ (black) and POMx (red) (b).  The correlation with higher doses of PJ that reduced lifespan and POMx 





1.5 Supplementary materials 
Table 8. Additional statistics for lifespan (P<0.05) 
a. PJ treated group 
 
Days/Dose (%) 0.01 0.1 1 3 5 10 25 
N2 
   16 16   
   30    
44   44 44   
daf-16 
20 20   20 20 20 
  36 36 36 36 36 
  52 52 52 52 52 
  67 67 67 67 67 
 
b. POMx treated group 
Days/Dose (µg/ml) 5 10 20 40 80 160 320 
N2 
  15     
27 27 27 27 27 27 27 
38 38 38 38 38 38 38 
 49 49 49 49 49 49 
daf-16 
25 25  25   25 
37 37  37   37 
46 46  46   46 
  
c. EA treated group 
Days/Dose (µM) DMSO 1 2 5 10 25 50 
N2        
daf-16 
 11      
      21 
  
 
d. UA treated group 
Days/Dose (µM) DMSO 1 2 5 10 25 50 
N2 
     15 15 
 26  26    
daf-16 
   13  13  
 22    22  
 31      






Table 9. Calculated GAE content in the doses of the PJ and POMx used in this study 
 
PJ [%] Calculated GAE [µg/ml]*  POMx [µg/ml] Calculated GAE [µg/ml]* 
0.01 0.2825  5 3.03 
0.1 2.825**  10 6.06** 
1 28.25**  20 12.12** 
3 84.75  40 24.24 
5 141.25  80 48.48 
10 282.5***  160 96.96 
25 706.25***  320 193.92 
 
*Calculation was based on [25] 
**Increased lifespan (P<0.05) 
***Reduce lifespan (P<0.05) 
 
Table 10. Correlation of estimated GAE with the dose-responses (A-shape) 
 Low doses High doses 
PJ y = 0.1388ln(x) - 0.0502 R² = 0.9999 y = 0.1452ln(x) - 0.1856 R² = 0.9995 
POMx y = -0.267ln(x) + 0.8962 R² = 0.9485 y = -0.069ln(x) + 0.4027 R² = 0.7102 
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CHAPTER V. CONCLUSIONS 
In a recent Danish report, patients who had vagal nerves removed 20 years earlier had 40% lower 
incidence of PD than control populations.  If dietary proteins were one potential etiology for PD, by 
transport to neurons from the gut, as hypothesized here, removal of the vagal nerve would have prevented 
or reduced this etiology pathway.  Symptoms of motor impairment are typical in PD patients, and 
dysfunction of aspects of the autonomic nervous system are often underrated, such as GI motility, rapid 
eye movement, etc.  The current study indicates potential transport of some dietary plant lectins from the 
GI tract to the DAergic neurons in C. elegans, with direct or indirect effects on these neurons and diverse 
effects on APS.  This observation may be related to the Braak and Hawkes’ hypothesized unknown 
etiologic agent for PD or related, for example, to damaged DAergic neurons those have been found in PD.  
If related, the process may be gradual, may be additive, related to the frequency of consumption of certain 
lectins, and may be determined by the association of lectins with other factors.  Certainly, there is potential 
for inputs from individual genetic susceptibility, varying sugar structures profiles in different cell 
membranes, the receptivity to endocytosis, a disorder or leakage of the GI lining, and dietary content.  Our 
observations are a tantalizing possible explanation for why dietary plants have been linked to a risk of 
developing PD. 
Our data from the C. elegans model indicate that the extension of lifespan by pomegranate is 
partially dependent on the daf-16 pathway, but mechanisms other than those involving polyphenols such 
as EA and its metabolites including UA may play a role as well.  The unique effects of PJ in reducing IFD 
suggest that the effects are not simply attributed to one component.  The results of the C. elegans studies 
provide useful information and suggest that, at the proper dilution, PJ may have optimal health benefits 
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